


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 401/04, 405/14, 401/14, 413/14, 471/14, 417/14, 409/14, 471/04		A1	(11) International Publication Number: WO 97/16440
			(43) International Publication Date: 9 May 1997 (09.05.97)
(21) International Application Number: PCT/EP96/04660		(74) Agent: DE CORTE, Filip; Janssen Pharmaceutica N.V., Patent Dept., Turnhoutseweg 30, B-2340 Beerse (BE).	
(22) International Filing Date: 25 October 1996 (25.10.96)			
(30) Priority Data: 95202929.6 30 October 1995 (30.10.95) EP		(81) Designated States: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BI, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(34) Countries for which the regional or international application was filed: DE et al.			
(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).			
(72) Inventors; and		Published With international search report.	
(75) Inventors/Applicants (for US only): JANSSENS, Frans, Eduard [BE/BE]; Tinststraat 79, B-2820 Bonheiden (BE). SOMMEN, François, Maria [BE/BE]; Langenberg 49, B-2323 Wortel (BE). SURLERAUX, Dominique, Louis, Nestor, Ghislaine [BE/BE]; Diegemstraat 48, B-1830 Machelen (BE). LEENAERTS, Joseph, Elisabeth [BE/BE]; Potbergstraat 35, B-2310 Rijkevorsel (BE). VAN ROOSBROECK, Yves, Emiel, Maria [BE/BE]; Zonderschotsesteenweg 26, B-2220 Heist-op den-Berg (BE).			

(54) Title: **1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES**

(57) Abstract

This invention concerns the compounds of formula (I), the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereoisomeric forms thereof, wherein *n* is 0, 1 or 2; *m* is 1 or 2, provided that if *m* is 2, then *n* is 1; *p* is 1 or 2; -Q is -O or -NR³; X is a covalent bond or a bivalent radical of formula -O-, -S-, -NR³-; R¹ is Ar¹, Ar¹C₁₋₆alkyl or di(Ar¹)C₁₋₆alkyl, wherein each C₁₋₆alkyl group is optionally substituted with hydroxy, C₁₋₆alkyloxy, oxo or a ketalized oxo substituent; R² is Ar², Ar²C₁₋₆alkyl, Het¹ or Het¹C₁₋₆alkyl; R³ is hydrogen or C₁₋₆alkyl; L is hydrogen; Ar³: C₁₋₆alkyl; C₁₋₆alkyl substituted with 1 or 2 substituents selected from hydroxy, C₁₋₆alkyloxy, Ar³, Ar³C₁₋₆alkyloxy and Het²; C₃₋₆alkenyl; Ar³C₃₋₆alkenyl; di(Ar³)C₃₋₆alkenyl or a radical of formula (a-1), (a-2), (a-3), (a-4) or (a-5); Ar¹, Ar² and Ar³ are each phenyl or substituted phenyl; Het¹ and Het² are each monocyclic or a bicyclic heterocycle; as substance-P antagonists; their preparation, compositions containing them and their use as a medicine.

Best Available Copy

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES

5

This invention concerns 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives having tachykinin antagonistic activity, in particular substance P antagonistic activity, and their preparation; it further relates to compositions comprising them, as well as their use as a medicine.


10

Substance P is a naturally occurring neuropeptide of the tachykinin family. There are ample studies showing that substance P and other tachykinins are involved in a variety of biological actions, and therefore, play an essential role in various disorders (Regoli et al., Pharmacological Reviews 46(4), 1994, p. 551-599, "Receptors and Antagonists for Substance P and Related Peptides"). The development of tachykinin antagonists has led to date to a series of peptide compounds of which might be anticipated that they are metabolically too labile to be employed as pharmaceutically active substances (Longmore J. et al., DN&P 8(1), February 1995, p. 5-23, "Neurokinin Receptors"). The present invention concerns nonpeptide tachykinin antagonists, in particular nonpeptide substance-P antagonists, which in general are metabolically more stable, and hence, may be more appropriate as pharmaceutically active substances.

Several nonpeptide tachykinin antagonists are disclosed in the art. For instance, EP-0,532,456-A, published on March 17, 1993 by Ciba-Geigy Corp., discloses 1-acylpiperidine compounds, in particular 2-arylalkyl-1-arylcarbonyl-4-piperidinamine derivatives, and their use as substance-P antagonists. EP-0,655,442-A, published on May 31, 1995 by Fujisawa Pharmaceutical Co. Ltd., discloses piperazine derivatives having tachykinin antagonistic activity.

The present compounds differ therefrom in that they invariably contain a 4-substituted- (piperazine or homopiperazine)-moiety in the 4-position of a piperidine- or homopiperidine group or in the 3-position of a pyrrolidine group, and by their favourable pharmacological properties.






The present invention concerns compounds of formula



-2-

the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein

- n is 0, 1 or 2;
 5 m is 1 or 2, provided that if m is 2, then n is 1;
 p is 1 or 2;
 =Q is =O or =NR³;
 X is a covalent bond or a bivalent radical of formula -O-, -S-, -NR³-;
 10 P¹ is Ar¹, Ar¹C₁₋₆alkyl or di(Ar¹)C₁₋₆alkyl, wherein each C₁₋₆alkyl group is optionally substituted with hydroxy, C₁₋₄alkyloxy, oxo or a ketalized oxo substituent of formula -O-CH₂-CH₂-O- or -O-CH₂-CH₂-CH₂-O-;
 R² is Ar², Ar²C₁₋₆alkyl, Het¹ or Het¹C₁₋₆alkyl;
 R³ is hydrogen or C₁₋₆alkyl;
 15 L is hydrogen; Ar³; C₁₋₆alkyl; C₁₋₆alkyl substituted with 1 or 2 substituents selected from hydroxy, C₁₋₆alkyloxy, Ar³, Ar³C₁₋₆alkyloxy and Het²;
 C₃₋₆alkenyl; Ar³C₃₋₆alkenyl; di(Ar³)C₃₋₆alkenyl or a radical of formula



- 20 wherein each q independently is 2, 3 or 4;
 each r is 0, 1, 2, 3 or 4;
 each Y¹ independently is a covalent bond, -O- or NR³;
 Y² is a covalent bond, C₁₋₄alkanediyl or -C₁₋₄alkylNR³-;

each -A=B- independently is a bivalent radical of formula -CH=CH-, -N=CH- or -CH=N-;

each R⁴ independently is hydrogen, C₁₋₆alkyl, Ar² or Ar²C₁₋₆alkyl;

R⁵ is hydrogen, C₁₋₆alkyl or Ar³;

5 R⁶ is C₁₋₆alkyl, Ar³, Ar³C₁₋₆alkyl, di(Ar³)C₁₋₆alkyl, Ar³C₃₋₇cycloalkyl, or indolyl;

10 R⁷ is Ar³; Ar³C₁₋₆alkyl; di(Ar³)C₁₋₆alkyl; C₁₋₆alkyl; C₃₋₇cycloalkyl; C₃₋₇cycloalkyl substituted with Ar³; oxazolyl; oxazolyl substituted with halo or C₁₋₆alkyl; thiazolyl; thiazolyl substituted with halo or C₁₋₆alkyl; imidazolyl; imidazolyl substituted with Ar³, C₁₋₆alkyl, Ar³C₁₋₆alkyl or halo; indolyl; indolyl substituted with C₁₋₄alkyl; 2,3,4-trihydroquinolyl; pyrrolidinyl or furanyl;

each R⁸ independently is hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl or a radical of formula

15 -Alk-R¹¹ (b-1) or
 -Alk-Z-R¹² (b-2);

wherein Alk is C₁₋₆alkanediyl;

Z is a bivalent radical of formula -O-, -S- or -NR³-;

20 R¹¹ is phenyl; phenyl substituted with 1 or 2 substituents selected from halo, C₁₋₆alkyl or C₁₋₆alkyloxy; furanyl; furanyl substituted with 1 or 2 substituents selected from C₁₋₆alkyl or hydroxyC₁₋₆alkyl; thienyl; thienyl substituted with 1 or 2 substituents selected from halo or C₁₋₆alkyl; oxazolyl; oxazolyl substituted with 1 or 2 C₁₋₆alkyl substituents; thiazolyl; thiazolyl substituted with 1 or 2 C₁₋₆alkyl substituents; pyridinyl or pyridinyl substituted with 1 or 2 C₁₋₆alkyl substituents;

R¹² is C₁₋₆alkyl or C₁₋₆alkyl substituted with hydroxy, carboxyl or C₁₋₆alkyloxycarbonyl;

30 Ar¹ is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, C₁₋₄alkyl, haloC₁₋₄alkyl, cyano, aminocarbonyl, C₁₋₄alkyloxy or haloC₁₋₄alkyloxy;

35 Ar² is naphthalenyl; phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from hydroxy, halo, cyano, nitro, amino, mono- or di(C₁₋₄alkyl)amino, C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkyloxy, haloC₁₋₄alkyloxy, carboxyl, C₁₋₄alkyloxycarbonyl, aminocarbonyl and mono- or di(C₁₋₄alkyl)aminocarbonyl;

- Ar³ is phenyl or phenyl substituted with 1, 2 or 3 substituents selected from halo, hydroxy, amino, nitro, aminocarbonyl, C₁₋₆alkyl, haloC₁₋₆alkyl or C₁₋₆alkyloxy;
- 5 Het¹ is a monocyclic heterocycle selected from pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl and benzothieryl; each monocyclic and bicyclic heterocycle may optionally be substituted on a carbon atom by 1 or 2 substituents selected from halo, C₁₋₄alkyl or mono-, di- or tri(halo)methyl; and
- 10 Het² is a heterocycle selected from 1,4-dihydro-5-oxo-tetrazol-1-yl, imidazo[1,2-a]pyridinyl, oxazolyl or imidazolyl; each of said heterocycles may be substituted with 1 or where possible 2 substituents selected from C₁₋₄alkyl and Ar³.
- 15

The heterocycles in the definition of Het¹ are preferably connected to the rest of the molecule, *i.e.* X, -C(=Q)- or C₁₋₆alkyl, by a carbon atom.

- As used in the foregoing definitions and hereinafter, halo is generic to fluoro, chloro, bromo and iodo; C₂₋₄alkyl defines straight and branched chain saturated hydrocarbon radicals having from 2 to 4 carbon atoms such as, for example, ethyl, propyl, butyl, 1-methylethyl, 2-methylpropyl and the like; C₁₋₄alkyl is meant to include C₂₋₄alkyl and methyl; C₁₋₅alkyl is meant to include C₁₋₄alkyl and the higher homologues thereof having 5 carbon atoms such as, for example, pentyl, 2-methylbutyl and the like; C₁₋₆alkyl is meant to include C₁₋₅alkyl and the higher homologues thereof having 6 carbon atoms such as, for example, hexyl, 2-methylpentyl and the like; C₁₋₄alkanediyl defines bivalent straight and branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for example, methylene, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl, and the like; C₁₋₆alkanediyl is meant to include C₁₋₄alkanediyl and the higher homologues thereof having from 5 to 6 carbon atoms such as, for example, 1,5-pentanediyl, 1,6-hexanediyl and the like; C₃₋₆alkenyl defines straight and branched chain hydrocarbon radicals containing one double bond and having from 3 to 6 carbon atoms such as, for example, 2-propenyl, 3-butenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl, 3-hexenyl and the like; and the carbon of said C₃₋₆alkenyl connected to the nitrogen atom of the piperazine or homopiperazine preferably is saturated.
- 20
- 25
- 30
- 35

As used in the foregoing definitions and hereinafter, haloC₁₋₄alkyl is defined as mono- or polyhalosubstituted C₁₋₄alkyl, in particular C₁₋₄alkyl substituted with 1 to 6 halogen

atoms, more in particular difluoro- or trifluoromethyl.

The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) are able to form. Said salts can conveniently be obtained by treating the base form of the compounds of formula (I) with appropriate acids such as, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-aminosalicylic, pamoic and the like acids.

The pharmaceutically acceptable addition salts as mentioned hereinabove are also meant to comprise the therapeutically active non-toxic base, in particular, a metal or amine addition salt forms which the compounds of formula (I) are able to form. Said salts can conveniently be obtained by treating the compounds of formula (I) containing acidic hydrogen atoms with appropriate organic and inorganic bases such as, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, *N*-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.

Conversely said salt forms can be converted by treatment with an appropriate base or acid into the free acid or base form.

The term addition salt as used hereinabove also comprises the solvates which the compounds of formula (I) as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like.

For isolation and purification purposes, it is also possible to use pharmaceutically unacceptable salts. Only the pharmaceutically acceptable, non-toxic salts are used therapeutically and those salts are therefore preferred.

The term "stereochemically isomeric forms" as used hereinbefore defines all the possible isomeric as well as conformational forms which the compounds of formula (I) may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture, more in particular the racemic mixture, of all possible stereochemically and conformationally isomeric forms, said mixtures containing all diastereomers, enantiomers and/or conformers of the basic molecular structure. More in

- particular, stereogenic centers may have the R- or S-configuration; substituents on bivalent cyclic saturated radicals may have either the *cis*- or *trans*-configuration; $>C=NR^3$ and C₃-alkenyl radicals may have the E- or Z-configuration. The compounds of formula (I) have at least two stereogenic centers; thus for compounds of which the actual stereochemical configuration is known, the relative stereodescriptors R* and S* may be used in accordance with the Chemical Abstracts rules (Chemical Substance Name Selection Manual (CA), 1982 Edition, Vol. III, Chapter 20). In those cases where the compounds of formula (I) were separated into its racemic *cis* and racemic *trans* isomers, or in those cases where the racemic *cis* or racemic *trans* isomers were separated into its pure enantiomeric forms, the stereochemically isomeric form which was first isolated was designated as "A" and the second as "B". All stereochemically isomeric forms of the compounds of formula (I) both in pure form or mixtures thereof are intended to be embraced within the scope of the present invention.
- Some of the compounds of formula (I) may also exist in their tautomeric form. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention. For instance, compounds of formula (I) wherein L is a radical of formula (a-1) wherein R⁵ is hydrogen, or a radical of (a-2) or (a-3) wherein Y¹ is -NH-, or a radical of formula (a-5) wherein R³ is hydrogen may exist in their corresponding tautomeric form. Also compounds of formula (I) wherein X is -NH- and =Q is =O may exist in their corresponding tautomeric form.

The N-oxide forms of the compounds of formula (I) are meant to comprise those compounds of formula (I) wherein one or several nitrogen atoms are oxidized to the so-called N-oxide, particularly those N-oxides wherein one or more of the piperazine-nitrogens are N-oxidized.

Whenever used hereinafter, the term "compounds of formula (I)" is meant to also include their N-oxide forms, their pharmaceutically acceptable addition salts, and their stereochemically isomeric forms.

A special group of compounds are those compounds of formula (I) wherein L is hydrogen; C₁-alkyl; C₁-alkyl substituted with hydroxy; C₃-alkenyl; Ar³; Ar³C₁-alkyl; di(Ar³)C₁-alkyl; Ar³C₃-alkenyl; di(Ar³)C₁-alkenyl; or a radical of formula (a-1), (a-2), (a-4) or (a-5) wherein

R⁷ is Ar³; Ar³C₁-alkyl; di(Ar³)C₁-alkyl; C₁-alkyl; C₃-cycloalkyl; C₃-cycloalkyl substituted with Ar³; oxazolyl; oxazolyl substituted with halo or C₁-alkyl; thiazolyl;

thiazolyl substituted with halo or C₁₋₆alkyl; imidazolyl; imidazolyl substituted with Ar³, C₁₋₆alkyl, Ar³C₁₋₆alkyl or halo; pyrrolidinyl or furanyl;

Ar³ is phenyl or phenyl substituted with 1, 2 or 3 substituents selected from halo, hydroxy, amino, aminocarbonyl, C₁₋₆alkyl, haloC₁₋₆alkyl or C₁₋₆alkyloxy;

- 5 Het¹ is a monocyclic heterocycle selected from pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from quinolinyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl and benzothienyl; each monocyclic and bicyclic heterocycle may
10 optionally be substituted on a carbon atom by 1 or 2 substituents selected from halo, C₁₋₄alkyl or mono-, di- or tri(halo)methyl.

A first group of interesting compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply :

- 15 a) R¹ is Ar¹C₁₋₆alkyl; or
- b) R² is Ar², Ar²C₁₋₆alkyl or Het¹; in particular, phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, cyano, nitro, amino, C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkyloxy and C₁₋₄alkyloxycarbonyl, more in particular, phenyl
20 substituted with 2 substituents selected from methyl and trifluoromethyl; or
- c) n is 0 or 1, in particular n is 1; or
- d) m is 1; or
25 e) p is 1 or 2, in particular p is 1; or
- f) =Q is =O; or
- 30 g) X is a covalent bond, -O- or -NR³-, in particular a covalent bond.

A second group of interesting compounds consists of those compounds of formula (I) wherein L is hydrogen, Ar³, Ar³C₁₋₆alkyl; di(Ar³)C₁₋₆alkyl; Ar³C₃₋₆alkenyl; C₁₋₆alkyl substituted with hydroxy; or

- 35 a radical of formula (a-2) wherein

R⁴ is hydrogen or Ar²;

r is 0 or 1;

Y¹ is a covalent bond, -O- or -NR³-; and

R⁷ is Ar³, C₃₋₇cycloalkyl substituted with Ar³, di(Ar³)methyl, pyrrolidinyl or furanyl; or
40

a radical of formula (a-4) wherein

Y² a covalent bond or methylene;

-A=B- is -CH=CH- or -N=CH-; and

5 R⁸ hydrogen, a radical of formula (b-1) wherein R¹¹ is methyl substituted oxazolyl, or a radical of formula (b-2) wherein Z is -O- and R¹² is C₁₋₆alkyl; or

a radical of formula (a-5) wherein

R⁴ is hydrogen;

q 2; and

10 R³ is hydrogen.

A third group of interesting compounds consists of those compounds of formula (I) wherein

q is 2 or 4;

15 -A=B- is -CH=CH- or -N=CH-;

R⁴ is hydrogen or Ar²;

R⁵ is hydrogen;

R⁶ is C₁₋₆alkyl or Ar³;

20 R⁷ is Ar³; di(Ar³)C₁₋₆alkyl; C₁₋₆alkyl; C₃₋₇cycloalkyl substituted with Ar³; thiazolyl; imidazolyl substituted with C₁₋₆alkyl or Ar³C₁₋₆alkyl; indolyl; indolyl substituted with C₁₋₄alkyl; 2,3,4-trihydroquinolyl; pyrrolidinyl or furanyl;

Z is -O-;

R¹¹ is phenyl substituted with halo; oxazolyl substituted with C₁₋₆alkyl; or

25 R¹² is C₁₋₆alkyl.

Of special interest are those compounds of formula (I) wherein R¹ is Ar¹C₁₋₆alkyl, R² is phenyl substituted with 2 substituents selected from methyl or trifluoromethyl, X is a covalent bond and =Q is =O.

30 Further of special interest are those compounds of formula (I) wherein n and m are 1 and p is 1 or 2.

Particular compounds are those compounds of formula (I) wherein

R¹ is phenylmethyl;

35 R² is phenyl substituted with 2 substituents selected from methyl or trifluoromethyl;

n, m and p are 1;

X is a covalent bond; and

$=Q$ is $=O$.

Also particular compounds are those compounds of formula (I) wherein L is a radical of formula (a-2) wherein

- 5 R^4 is hydrogen or phenyl;
 r is 0 or 1;
 Y^1 is a covalent bond, -O- or -NH-;
 R^7 is pyrrolidinyl; furanyl; 1-phenylcyclohexanyl; diphenylmethyl; or phenyl
 10 substituted with 1, 2 or 3 substituents each independently selected from
 methyl, methoxy or chloro.

Preferred compounds are those particular compounds that have a *trans* configuration.

- 15 Other preferred compounds are those particular compounds that have a *cis* configuration.

Still other preferred compounds are those compounds of formula (I) wherein

- R^1 is phenylmethyl;
 R^2 is phenyl substituted with 2 substituents selected from methyl or
 trifluoromethyl;
 20 n, m and p are 1;
 X is a covalent bond;
 $=Q$ is $=O$;
 L is a radical of formula (a-2) wherein
 R^4 is hydrogen;
 25 r is 1;
 Y^1 is -NH-; and
 R^7 is phenyl substituted with 2 methyl substituents.


Most preferred are those compounds selected from

- 30 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethyl-
 phenyl)-1-piperazine acetamide;
 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(1-phenyl-
 cyclohexyl)-1-piperazine acetamide;
 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-[4-[α -(1-pyrrolidinylcarbonyl)-
 35 benzyl]-1-piperazinyl]piperidine;
 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-[1-[(2-methyl-5-oxazolyl)methyl]-1H-
 benzimidazol-2-yl]-1-piperazinyl]-2-(phenylmethyl)piperidine;
 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(4-trifluoromethylphenyl)methyl]-4-
 piperidinyl]-N-(2,6-dimethylphenyl)-1-piperazine acetamide;

4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide; the *N*-oxides, the stereoisomeric forms and the pharmaceutically acceptable addition salts thereof.

- 5 Particularly interesting stereoisomeric forms are
 (+)-(B)-*trans*-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide; and
 (-)-(B)-*cis*-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide, and the pharmaceutically acceptable
 10 addition salts thereof, especially the (L)-malic acid form.


The compounds of formula (I) can be prepared by reductively *N*-alkylating an intermediate of formula (III) with an intermediate of formula (II). Said reductive *N*-alkylation may be performed in a reaction-inert solvent such as, for example, dichloromethane,
 15 ethanol, toluene or a mixture thereof, and in the presence of an appropriate reducing agent such as, for example, a borohydride, e.g. sodium borohydride, sodium cyanoborohydride or triacetoxy borohydride. In case a borohydride is used as a reducing agent, it may be convenient to use a complex-forming agent such as, for example, titanium(IV)isopropylate as described in J. Org. Chem, 1990, 55, 2552-2554. Using
 20 said complex-forming agent may also result in an improved *cis/trans* ratio in favour of the *trans* isomer. It may also be convenient to use hydrogen as a reducing agent in combination with a suitable catalyst such as, for example, palladium-on-charcoal or platinum-on-charcoal. In case hydrogen is used as reducing agent, it may be advantageous to add a dehydrating agent to the reaction mixture such as, for example,
 25 aluminium *tert*-butoxide. In order to prevent the undesired further hydrogenation of certain functional groups in the reactants and the reaction products, it may also be advantageous to add an appropriate catalyst-poison to the reaction mixture, e.g., thiophene or quinoline-sulphur. Stirring and optionally elevated temperatures and/or
 30 pressure may enhance the rate of the reaction.



In this and the following preparations, the reaction products may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally
 35 known in the art such as, for example, extraction, crystallization, trituration and

chromatography.


The compounds of formula (I) can also be prepared by reacting an intermediate of formula (IV) wherein W^1 is an appropriate leaving group such as, for example, a halogen, e.g. chloro or bromo, or a sulfonyloxy leaving group, e.g. methanesulfonyloxy or benzenesulfonyloxy, with an intermediate of formula (V). The reaction can be performed in a reaction-inert solvent such as, for example, a chlorinated hydrocarbon, e.g. dichloromethane, an alcohol, e.g. ethanol, or a ketone, e.g. methyl isobutylketone, and in the presence of a suitable base such as, for example, sodium carbonate, sodium hydrogen carbonate or triethylamine. Stirring may enhance the rate of the reaction. The reaction may conveniently be carried at a temperature ranging between room temperature and reflux temperature.



15

The compounds of formula (I) may also be converted into each other following art-known transformations. In particular, the compounds of formula (I) wherein L is other than hydrogen, said L being represented by L' and said compounds being represented by formula (I-a), can also be prepared by reacting a compound of formula (I) wherein L is hydrogen, said compounds being represented by formula (I-b), with an intermediate of formula (VI) wherein W^2 is an appropriate leaving group such as, for example, a halogen, e.g. chloro or bromo, or a sulfonyloxy leaving group, e.g. methanesulfonyloxy or benzenesulfonyloxy, at reaction conditions which are similar to those for the reaction between intermediates of formula (IV) and (V).


25



Compounds of formula (I-b) may be prepared by reductively *N*-alkylating a piperazine derivative of formula (VII) wherein P^1 is a protective group such as, for example, benzyl, with an intermediate of formula (II). Said reaction may be performed in a similar way as described hereinabove for the reductive *N*-alkylation using intermediates (II) and (III). The thus formed compound of formula (I-c) may then be deprotected using art-


30

known deprotection techniques. Depending on the nature of the protective group P¹, compounds of formula (I-c) may be part of the scope of the compounds of formula (I).



5

Alternatively, compounds of formula (I-b) may be prepared by first reductively *N*-alkylating a piperazine derivative of formula (VII) wherein P¹ is a protective group such as, for example, halo, with an intermediate of formula (VIII) using the same procedure as described hereinabove for the reductive *N*-alkylation using intermediates (II) and (III). The thus formed intermediate of formula (XI) may then be reacted with an intermediate of formula (IV) in a reaction-inert solvent and optionally in the presence of a suitable base such as, for example, triethylamine, to form a compound of formula (I-c), which may then be deprotected using art-known deprotection techniques.



15


The compounds of formula (I-b) are deemed to be of particular use in the synthesis of other compounds of formula (I).

20 The compounds of formula (I) may also be converted to the corresponding *N*-oxide

forms following art-known procedures for converting a trivalent nitrogen into its *N*-oxide form. Said *N*-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzenecarboperoxoic acid, peroxyalkanoic acids, e.g. peroxyacetic acid, alkylhydroperoxides, e.g. *tert*-butyl hydroperoxide. Suitable solvents are, for example, water, lower alkanols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.

The starting materials and some of the intermediates are known compounds and are commercially available or may be prepared according to conventional reaction procedures generally known in the art. For example, intermediates of formula (III), (IV) and (VI) may be prepared according to art-known procedures.


Intermediates of formula (II) may be prepared by condensing an intermediate of formula (IV) with an intermediate of formula (VIII) analogous to the procedure described in EP-0,532,456-A.



The preparation of intermediates of formula (VIII) is also described in EP-0,532,456-A. However, intermediates of formula (VIII) wherein R^1 is optionally substituted $\text{Ar}^1\text{C}_1\text{-6alkyl}$ or $\text{di}(\text{Ar}^1)\text{C}_1\text{-6alkyl}$, said R^1 being represented by $-\text{CH}(\text{R}^{1a})_2$ and said intermediates being represented by formula (VIII-a), may also be prepared as depicted in scheme 1.


-14-

Scheme 1




- 5 In scheme 1, the intermediates of formula (IX-b) may be prepared by reacting an intermediate of formula (IX-a) with an aldehyde or a ketone of formula (X). The C_{1-6} alkylcarbamate moiety in the intermediates of formula (IX-b) may be converted into a fused oxazolidone which in turn may be reduced to an intermediate of formula (IX-d). Said intermediate (IX-d) may in turn be deprotected, thus forming an intermediate of
- 10 formula (VIII-a). Subsequently, intermediates of formula (VIII-a) may be reacted with an intermediate of formula (IV) to prepare intermediates of formula (II) wherein R^1 is defined as $-CH(R^{1a})_2$, said intermediates being represented by formula (II-a).

- Said intermediates of formula (II-a) may also be prepared by first reacting intermediate
- 15 (IX-d) with intermediate (IV) in the presence of a suitable base to form an intermediate of formula (XII), which may subsequently be deprotected. These reactions and those performed in scheme 1 may all be conducted following conventional methods that are generally known in the art.




Intermediates of formula (V) may suitably be prepared by reacting an intermediate of formula (VIII-1), being a protected intermediate of formula (VIII) with a protecting group P² such as, for example, a C₁₋₆alkyloxycarbonyl group, with an intermediate of formula (III) according to the previously described reductive N-alkylation procedure, and subsequently deprotecting the thus formed intermediate.



In particular, intermediates of formula (V) wherein R¹ is -CH(R^{1a})₂, said intermediates being represented by formula (V-a), may be prepared as is depicted in scheme 2.

Scheme 2



The ketalized intermediate of formula (IX-c) may be transformed to the corresponding ketone of formula (IX-e) which subsequently may be reductively aminated with a piperazine- or homopiperazine derivative of formula (III). The thus obtained intermediate may then be reduced with a suitable reducing agent to an intermediate of formula (V-a).

Pure stereochemically isomeric forms of the compounds of formula (I) may be obtained by the application of art-known procedures. Diastereomers may be separated by physical methods such as selective crystallization and chromatographic techniques, e.g., counter-current distribution, liquid chromatography and the like.

The compounds of formula (I) as prepared in the hereinabove described processes are generally racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of formula (I) which are sufficiently basic or acidic may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid, respectively chiral base. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali or acid. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

The compounds of formula (I) have valuable pharmacological properties in that they interact with tachykinin receptors and they antagonize tachykinin-induced effects, especially substance P-induced effects, both *in vivo* and *in vitro* and are thus of use in the treatment of tachykinin-mediated diseases, and in particular in substance P-mediated diseases.

Tachykinins, also referred to as neurokinins, are a family of peptides among which substance P (SP), neurokinin A (NKA), neurokinin B (NKB) and neuropeptide K (NPK) may be identified. They are naturally occurring in mammals, including human beings, and are distributed throughout the central and peripheral nervous system, where they act as neurotransmitters or neuromodulators. Their actions are mediated through several subtypes of receptors, such as, for example, NK₁, NK₂ and NK₃ receptors. Substance P displays highest affinity for NK₁ receptors, whereas NKA preferentially binds to NK₂ receptors and NKB preferentially binds to NK₃ receptors. However, the selectivity of these tachykinins is relatively poor and under physiological conditions the action of any of these tachykinins might be mediated by activation of more than one receptor type.

Substance P and other neurokinins are involved in a variety of biological actions such as pain transmission (nociception), neurogenic inflammation, smooth muscle contraction, plasma protein extravasation, vasodilation, secretion, mast cell degranulation, and also in

activation of the immune system. A number of diseases are deemed to be engendered by activation of neurokinin receptors, in particular the NK₁ receptor, by excessive release of substance P and other neurokinins in particular cells such as cells in the neuronal plexi of the gastrointestinal tract, unmyelinated primary sensory afferent neurons, sympathetic
5 and parasympathetic neurons and nonneuronal cell types (DN&P 8(1), February 1995, p. 5-23, "Neurokinin Receptors" by Longmore J. et al.; Pharmacological Reviews 46(4), 1994, p. 551-599, "Receptors and Antagonists for Substance P and Related Peptides" by Regoli et al.).

10 The compounds of the present invention are potent inhibitors of neurokinin-mediated effects, in particular those mediated via the NK₁ receptor, and may therefore be described as tachykinin antagonists, especially as substance P antagonists, as indicated *in vitro* by the antagonism of substance P-induced relaxation of pig coronary arteries which is described hereinafter. The binding affinity of the present compounds for the human,
15 guinea-pig and gerbil neurokinin receptors may be determined *in vitro* in a receptor binding test using ³H-substance-P as radioligand. The subject compounds also show substance-P antagonistic activity *in vivo* as may be evidenced by, for instance, the antagonism of substance P-induced plasma extravasation in guinea-pigs, or the antagonism of drug-induced emesis in ferrets (Watson et al., Br. J. Pharmacol. 115, 84-
20 94, 1995).

In view of their capability to antagonize the actions of tachykinins by blocking the tachykinin receptors, and in particular antagonizing the actions of substance P by blocking the NK₁ receptor, the subject compounds are useful in the prophylactic and
25 therapeutic treatment of tachykinin-mediated diseases such as, for example,

- pain, in particular traumatic pain such as postoperative pain; traumatic avulsion pain such as brachial plexus; chronic pain such as arthritic pain such as occurring in osteo-, rheumatoid or psoriatic arthritis; neuropathic pain such as post-herpetic neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia, fibromyalgia, causalgia,
30 peripheral neuropathy, diabetic neuropathy, chemotherapy-induced neuropathy, AIDS-related neuropathy, occipital neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, reflex sympathetic dystrophy, phantom limb pain; various forms of headache such as migraine, acute or chronic tension headache, temporomandibular pain, maxillary sinus pain, cluster headache; odontalgia; cancer pain; pain of visceral
35 origin; gastrointestinal pain; nerve entrapment pain; sport's injury pain; dysmenorrhoea; menstrual pain; meningitis; arachnoiditis; musculoskeletal pain; low back pain e.g. spinal stenosis; prolapsed disc; sciatica; angina; ankylosing

- spondylitis; gout; burns; scar pain; itch; and thalamic pain such as post stroke thalamic pain;
- respiratory and inflammatory diseases, in particular inflammation in asthma, influenza, chronic bronchitis and rheumatoid arthritis; inflammatory diseases of the gastrointestinal tract such as Crohn's disease, ulcerative colitis, inflammatory bowel disease and non-steroidal anti-inflammatory drug induced damage; inflammatory diseases of the skin such as herpes and eczema; inflammatory diseases of the bladder such as cystitis and urge incontinence; and eye and dental inflammation;
 - emesis, i.e. nausea, retching and vomiting, including acute emesis, delayed emesis and anticipatory emesis, no matter how emesis is induced, for example, emesis may be induced by drugs such as cancer chemotherapeutic agents such as alkylating agents, e.g. cyclophosphamide, carmustine, lomustine and chlorambucil; cytotoxic antibiotics, e.g. dactinomycin, doxorubicin, mitomycin-C and bleomycin; anti-metabolites, e.g. cytarabine, methotrexate and 5-fluorouracil; vinca alkaloids, e.g. etoposide, vinblastine and vincristine; and others such as cisplatin, dacarbazine, procarbazine and hydroxyurea; and combinations thereof; radiation sickness; radiation therapy, e.g. irradiation of the thorax or abdomen, such as in the treatment of cancer; poisons; toxins such as toxins caused by metabolic disorders or by infection, e.g. gastritis, or released during bacterial or viral gastrointestinal infection; pregnancy; vestibular disorders, such as motion sickness, vertigo, dizziness and Ménière's disease; post-operative sickness; gastrointestinal obstruction; reduced gastrointestinal motility; visceral pain, e.g. myocardial infarction or peritonitis; migraine; increased intracranial pressure; decreased intracranial pressure (e.g. altitude sickness); opioid analgesics, such as morphine; and gastro-oesophageal reflux disease, acid indigestion, over-indulgence of food or drink, acid stomach, sour stomach, waterbrash/regurgitation, heartburn, such as episodic heartburn, nocturnal heartburn, and meal-induced heartburn and dyspepsia;
 - central nervous system disorders, in particular psychoses such as schizophrenia, mania, dementia or other cognitive disorders e.g. Alzheimer's disease; anxiety; AIDS-related dementia; diabetic neuropathy; multiple sclerosis; depression; Parkinson's disease; and dependence on drugs or substances of abuse;
 - allergic disorders, in particular allergic disorders of the skin such as urticaria, and allergic disorders of the airways such as rhinitis;
 - gastrointestinal disorders, such as irritable bowel syndrome;
 - skin disorders, such as psoriasis, pruritis and sunburn;
 - vasospastic diseases, such as angina, vascular headache and Reynaud's disease;
 - cerebral ischaemia, such as cerebral vasospasm following subarachnoid haemorrhage;

- stroke, epilepsie, head trauma, spinal cord trauma and ischemic neuronal damage;
- fibrosing and collagen diseases, such as scleroderma and eosinophilic fascioliasis;
- disorders related to immune enhancement or suppression, such as systemic lupus erythematosus;
- 5 - rheumatic diseases, such as fibrositis;
- neoplastic disorders;
- cell proliferation; and
- cough.

10 The compounds of the present invention have a favourable metabolic stability and exhibit good oral availability. They also have an advantageous onset and duration of action. The compounds of formula (I) also have the ability to penetrate the central nervous system as may be demonstrated *in vivo* by their inhibitory effect on the change in
15 behaviour induced by intracerebroventricular-applied substance P in the gerbil.

In view of the utility of the compounds of formula (I), there is provided a method of treating warm-blooded animals, including humans, suffering from tachykinin-mediated diseases as mentioned hereinabove, in particular, pain, emesis or asthma. Said method comprises the systemic administration of an effective tachykinin antagonizing amount of
20 a compound of formula (I), a *N*-oxide form, a pharmaceutically acceptable addition salt or a possible stereoisomeric form thereof, to warm-blooded animals, including humans. Hence, the use of a compound of formula (I) as a medicine is provided, and in particular a medicine to treat pain, emesis or asthma.

25 For ease of administration, the subject compounds may be formulated into various pharmaceutical forms for administration purposes. To prepare the pharmaceutical compositions of this invention, a therapeutically effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which may take a wide
30 variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils,
35 alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most

advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable solutions containing compounds of formula (I) may be formulated in an oil for prolonged action. Appropriate oils for this purpose are, for example, peanut oil, sesame oil, cottonseed oil, corn oil, soy bean oil, synthetic glycerol esters of long chain fatty acids and mixtures of these and other oils. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause any significant deleterious effects on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on or as an ointment. Acid or base addition salts of compounds of formula (I) due to their increased water solubility over the corresponding base or acid form, are obviously more suitable in the preparation of aqueous compositions.

In order to enhance the solubility and/or the stability of the compounds of formula (I) in pharmaceutical compositions, it can be advantageous to employ α -, β - or γ -cyclodextrins or their derivatives, in particular hydroxyalkyl substituted cyclodextrins, e.g. 2-hydroxypropyl- β -cyclodextrin. Also co-solvents such as alcohols may improve the solubility and/or the stability of the compounds of formula (I) in pharmaceutical compositions.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

- Those of skill in the treatment of tachykinin mediated diseases could determine the effective therapeutic daily amount from the test results presented hereinafter. An effective therapeutic daily amount would be from about 0.001 mg/kg to about 40 mg/kg body weight, more preferably from about 0.01 mg/kg to about 5 mg/kg body weight. It may be appropriate to administer the therapeutically effective dose once daily or as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 0.05 mg to 500 mg, and in particular, 0.5 mg to 50 mg of active ingredient per unit dosage form.
- 10 The exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight and general physical condition of the particular patient as well as other medication the patient may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased
- 15 depending on the response of the treated patient and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective daily amount ranges mentioned hereinabove are therefore only guidelines.

20 The following examples are intended to illustrate and not to limit the scope of the present invention.

Experimental Part

Hereinafter "RT" means room temperature, "THF" means tetrahydrofuran, "DIPE" means diisopropylether, "DCM" means dichloromethane and "DMF" means *N,N*-dimethylformamide.

25

A. Preparation of the intermediate compounds

Example A.1

- 30 a) A mixture of (\pm)-1,1-dimethyl 7-(phenylmethyl)-1,4-dioxo-8-azaspiro[4,5]decane-8-carboxylate (13 g; prepared according to the method described in EP-A-532,456) in HCl (6N; 130 ml) was stirred and refluxed for 3 hours. The reaction mixture was cooled, alkalized with aqueous NaOH (50 %) and extracted with DCM. The organic layer was separated, dried, filtered, and the filtrate, which contained (\pm)-2-(phenylmethyl)-4-piperidinone (intermediate 1), was used in next reaction step.
- 35 b) A mixture of the filtrate obtained in the previous reaction step, 3,5-dimethylbenzoyl chloride (7.4 g) and triethylamine (11 ml) was stirred overnight at RT. The reaction mixture was extracted with dilute NaOH solution. The organic layer was separated, dried, filtered and the solvent evaporated. The residue was crystallized from DIPE. The

precipitate was filtered off and dried, yielding 7.44 g (58%) of (±)-1-(3,5-dimethylbenzoyl)-2-(phenylmethyl)-4-piperidinone (intermediate 2; mp. 107.8°C).

Example A.2

- 5 a) A mixture of (±)-1,1-dimethyl 7-(phenylmethyl)-1,4-dioxo-8-azaspiro[4,5]decane-8-carboxylate (33.34 g; prepared according to the method described in EP-A-532,456) in HCl (6N; 250 ml) was stirred at 70 °C for 1 hour and 30 minutes. The mixture was cooled, alkalinized with NaOH while cooling to 25°C, and extracted with DCM (100 ml). The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂.
10 Triethylamine (20.2 g), followed by 3,5-bis(trifluoromethyl)benzoyl chloride (27.7 g) dissolved in a little DCM were added and the mixture was stirred for 2 hours. The mixture was extracted with water, and the layers were separated. The organic layer was dried, filtered and the solvent evaporated. The residue was crystallized from DIPE, the precipitate was filtered off and dried, yielding 18.34 g product. The mother layer was
15 evaporated and the residue was crystallized from DIPE. The precipitate was filtered off and dried, yielding 6.51 g of product. The two fractions were put together and taken up in water and DCM, NaOH was added and the mixture was extracted. The organic layer was dried, filtered and the solvent evaporated, yielding 16.14 g (38%) of (±)-1-[3,5-bis-(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinone (intermediate 3;
20 mp. 102.5°C).

Example A.3

- A mixture of pyrrolidine (2.13 g) and triethylamine (6.06 g) in DCM (100 ml) was stirred at -10°C. 2-chloro-2-phenylacetylchloride (5.67 g) was added slowly and
25 dropwise. The mixture was allowed to warm to RT and was then stirred overnight. The mixture was extracted with water and K₂CO₃. The separated organic layer was dried, filtered and the solvent was evaporated. The residue was crystallized from DIPE and the precipitate was filtered off and dried, yielding 3.25 g (48 %) of fraction 1. The mother layer was separated and the solvent was evaporated. The residue was crystallized from
30 DIPE and the precipitate was filtered off and dried, yielding 0.29 g (5 %) of fraction 2. Both fractions were combined, thus yielding 3.54 g (53 %) of (±)-1-(2-chloro-2-phenylacetyl)pyrrolidine (intermediate 4; mp. 88.5 °C).

Example A.4

- 35 Sodium hydride (2 g) was added portionwise to a solution of 3,5-dimethylphenol (6.1 g) in DMF (50 ml). The mixture was stirred for 30 minutes and added dropwise at a temperature below 30 °C to a solution of 2-chloro-2-phenylacetylchloride (9.45 g) in DMF (50 ml). The mixture was stirred overnight, decomposed with water (5 ml) and

- the solvent was evaporated. Water was added and the mixture was extracted with DCM. The separated organic layer was dried, filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent : hexane/DIPE 100/0, 98/2 and 95/5). The pure fractions were collected and the solvent was evaporated [residue; yielding 10.82 g (79%)]. A small amount of the obtained residue was crystallized from DIPE, the precipitate was filtered off and the solvent was evaporated, yielding 1 g of (±)-3,5-dimethylphenyl α-chlorobenzeneacetate (intermediate 5; mp. 79.0 °C).

Example A.5

- a) A mixture of (±)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-(1-piperazinyl)piperidine (0.0127 mol), chloroacetonitrile (0.013 mol) and sodium carbonate (0.013 mol) in methylisobutyl keton (100ml) was stirred and refluxed. The mixture was cooled and water was added. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent: CH₂Cl₂/CH₃OH 100/0, 99.5/0.5 and 99/1). The pure fractions were collected and the solvent was evaporated, yielding 3.64g (53%) of (±)-*cis*-1-[3,5-bis-(trifluoromethyl)benzoyl]-4-[4-(cyanomethyl)-1-piperazinyl]-2-(phenylmethyl)piperidine (intermediate 6).
- b) A mixture of intermediate 6 (0.0067 mol) in THF (150 ml) was hydrogenated at 20°C with Raney Nickel (1 g) as a catalyst. After uptake of hydrogen, the catalyst was filtered off and the filtrate was evaporated, yielding 3.77 g of (±)-*cis*-4-[4-(2-aminoethyl)-1-piperazinyl]-1-[3,5-(trifluoromethyl)benzoyl]-2-(phenylmethyl)piperidine (intermediate 7).

Example A.6

- A mixture of 1-(phenylmethyl)-4-piperidinone (0.2 mol) and 1-methylpiperazine (0.2 mol) in methanol (500 ml) was hydrogenated for 8 hours with palladium on activated carbon (10%, 2.5 g) as a catalyst. After uptake of hydrogen, the catalyst was filtered off and the filtrate was evaporated. A mixture of di-*tert*-butyl dicarbonate (0.2 mol) in THF (500 ml) was added to the residue and hydrogenated again with palladium on activated carbon (10%, 2.5 g) as a catalyst. After uptake of hydrogen, the catalyst was filtered off and the filtrate was evaporated. The residue was purified over silica gel on a glass filter (eluent: CH₂Cl₂/CH₃OH 95/5). The pure fractions were collected and the solvent was evaporated, yielding 45.3 g (80%) of 1,1-dimethylethyl 4-(4-methyl-1-piperazinyl)-1-piperidinecarboxylate (intermediate 8).

Example A.7

- a) A mixture of 4-methoxypyridine (0.4 mol) in THF (1000 ml) was stirred and cooled in

- a 2-propanol/ CO_2 bath. Ethyl chloroformate (0.4 mol) was added dropwise and the mixture was stirred for 3 hours while cooling (mixture I). In another round-bottom flask, the Grignard-reagent was prepared: Mg (0.44 mol) was stirred in a small amount of $(\text{C}_2\text{H}_5)_2\text{O}$. Some I_2 was added. A small amount of 1,2-dichloro-4-(chloromethyl)-benzene was added. Then, 1,2-dichloro-4-(chloromethyl)benzene (0.4 mol) in $(\text{C}_2\text{H}_5)_2\text{O}$ (600 ml) was added dropwise at reflux temperature. The mixture was stirred for one hour (mixture II). The Grignard-reagent was decanted off, added to mixture I at $< -40^\circ\text{C}$, and the resulting reaction mixture was stirred, allowing the temperature to reach RT. The reaction mixture was stirred for one hour at RT. HCl (10 %, 800 ml) was added and the mixture was stirred for 30 minutes, then CH_2Cl_2 was added. The organic layer was separated, dried, filtered and the solvent evaporated, yielding 57.8 g (44%) of (\pm)-ethyl 6-[(3,4-dichlorophenyl)methyl]-1,2,3,4-tetrahydro-4-oxo-1-pyridine-carboxylate (intermediate 9).
- b) Intermediate 9 (0.176 mol) in THF (880 ml) was stirred under a N_2 flow, and cooled to -78°C . L-selectride (0.264 mol) was added dropwise at -78°C . The reaction mixture was stirred for 1 hour, then poured out into water. DIPE was added. The organic layer was separated, washed with an aqueous NaHCO_3 solution, with an aqueous NaCl solution, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 90/10). The desired fractions were collected and the solvent was evaporated, yielding 20.2 g (34.8%) of (\pm)-ethyl 2-[(3,4-dichlorophenyl)methyl]-4-oxo-1-piperidinecarboxylate (intermediate 10).
- c) Titanium(IV)isopropoxide (0.0269 mol) was added to a mixture of intermediate 10 (0.0224 mol) and intermediate 10 (0.0224 mol) in DCM (11 ml). The mixture was stirred at RT for 3 hours. Sodium cyanoborohydride (0.0224 mol) and then ethanol (10 ml) were added. The mixture was stirred at RT for 48 hours. Water was added and the mixture was stirred. CH_2Cl_2 was added and the mixture was stirred. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by HPLC over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 100/0 and 98/2). The pure fractions were collected and the solvent was evaporated. The residue was purified by reversed phase chromatography (eluent: NH_4OAc (0.5% in H_2O)/ CH_3OH 20/80). Two pure fractions were collected and their solvents were evaporated. The residue was dried and ground, yielding 2 g (16%) of (\pm)-ethyl *trans*-2-[(3,4-dichlorophenyl)methyl]-4-[4-[2-[(2,6-dimethylphenyl)amino]-2-oxoethyl]-1-piperazinyl]-1-piperidinecarboxylate (intermediate 11) and 3.5g (28%) of (\pm)-ethyl *cis*-2-[(3,4-dichlorophenyl)methyl]-4-[4-[2-[(2,6-dimethylphenyl)amino]-2-oxoethyl]-1-piperazinyl]-1-piperidinecarboxylate (intermediate 12).

- d) A mixture of intermediate 11 (0.0034 mol) and potassium hydroxide (0.034 mol) in 2-propanol (150 ml) was stirred and refluxed for 4 days. The solvent was evaporated. The residue was taken up in CH₂Cl₂/water. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/(CH₃OH/NH₃) 95/5). The pure fractions were collected and the solvent was evaporated, yielding 0.5 g (30%) of (±)-*trans*-4-[2-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazineacetamide (intermediate 13).

10 Example A 8

- a) *Sec*-butyllithium (0.066 mol) was added to a mixture of 1,1-dimethylethyl 1,4-dioxo-8-azaspiro[4.5]-8-carboxylate (0.06 mol) in *N,N,N',N'*-tetramethylethylenediamine (22.6 ml) and (C₂H₅)₂O (100 ml). The mixture was stirred at -70°C for 3 hours. 3,5-difluorobenzaldehyde (0.07 mol) was added dropwise at -70°C. The mixture was allowed to warm to RT. Water (50 ml) and DIPE were added. The aqueous layer was separated and extracted with CH₂Cl₂. The combined organic layer was dried, filtered and the solvent was evaporated. Toluene was added and evaporated again, yielding 23 g of (±)-1,1-dimethylethyl 7-[(3,5-difluorophenyl)hydroxymethyl]-1,4-dioxo-8-azaspiro[4.5]-8-carboxylate (intermediate 14)
- b) A mixture of intermediate 14 (0.06 mol) and 2-methyl-2-propanol, potassium salt (0.72 g) in toluene (110 ml) was stirred and refluxed for 2 hours. The solvent was evaporated. The residue was stirred in petroleum ether and a small amount of water, and decanted. The residue was dissolved in CH₂Cl₂, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 100/0, 99/1 and 98/2). Two pure fractions were collected and their solvents were evaporated, yielding 9.2 g (49%) of (±)-3-(3,5-difluorophenyl)tetrahydro-spiro[1,3-dioxolan-2,5'(3'H)-1H-oxazolo[3,4-a]pyridin]-1-one (intermediate 15)
- c) A mixture of intermediate 15 (0.03 mol) in methanol (250 ml) was hydrogenated at 50°C with palladium on activated carbon (10%, 2 g) as a catalyst. After uptake of hydrogen, the catalyst was filtered off and the filtrate was evaporated. The residue was purified over silica gel on a glass filter (eluent: CH₂Cl₂/CH₃OH 100/0, 98/2 and 95/5 and CH₂Cl₂/(CH₃OH/NH₃) 95/5). The desired fractions were collected and the solvent was evaporated, yielding 1.9 g (39 %) of (±)-7-[(3,5-difluorophenyl)methyl]-1,4-dioxo-8-azaspiro[4.5]decane (intermediate 16).
- d) A mixture of intermediate 16 (0.012 mol) in HCl 6N (30ml) was stirred at 75°C for 2 hours. The mixture was cooled, poured out into ice and a NaOH solution and extracted with CH₂Cl₂. The organic layer was separated, dried and filtered, yielding

2.7 g of (±)-2-[(3,4-difluorophenyl)methyl]-4-piperidinone (intermediate 17).

e) A mixture of 3,5-trifluoromethylbenzoyl chloride (0.012 mol) in a small amount of CH₂Cl₂ was added dropwise to a stirred mixture of intermediate 17 (0.012 mol) and *N,N*-diethylethanamine (0.024 mol). The mixture was stirred at RT for 1 hour and water
5 was added. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent: CH₂Cl₂/CH₃OH 100/0 and 99.5/0.5). The pure fractions were collected and the solvent was evaporated, yielding 2.7 g (48%) of (±)-1-[3,5-bis(trifluoromethyl)benzoyl]-
10 2-[(3,5-difluorophenyl)methyl]-4-piperidinone (intermediate 18).

Example A.9

Sec-butyllithium (0.63 mol) was added at -78°C under N₂ flow to a solution of 1,1-dimethylethyl 1,4-dioxo-8-azaspiro[4.5]-8-carboxylate (0.57 mol) and *N,N,N',N'*-tetramethylethylenediamine (1.14 mol) in (C₂H₅)₂O (1000 ml). One hour after complete
15 addition, a mixture of 3-(trifluoromethyl)benzaldehyde (0.57 mol) in (C₂H₅)₂O (200 ml) was added. The mixture was allowed to warm to RT and then stirred at RT for 16 hours. The solvent was evaporated. A mixture of 2-methyl-2-propanol, potassium salt (0.2 mol) in toluene (500 ml) was added. The mixture was stirred at 80°C for 5 hours. The
20 solvent was evaporated. The residue was heated with a saturated NH₄Cl solution and extracted with CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was suspended in DIPE, filtered off and dried. This fraction was dissolved in CH₃OH (250 ml) and the mixture was hydrogenated with
25 palladium on activated carbon (10%, 3 g) as a catalyst. After uptake of hydrogen, the catalyst was filtered off and the filtrate was evaporated. The residue was purified over silica gel on a glass filter (eluent: CH₂Cl₂/CH₃OH 95/5). The pure fractions were collected and the solvent was evaporated. This fraction was dissolved in HCl (6N, 100 ml) and CH₃OH (100 ml) and the mixture was stirred at 50°C for 8 hours. The organic
30 solvent was evaporated. The concentrate was washed with a saturated K₂CO₃ solution and extracted with CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent: CH₂Cl₂/CH₃OH 95/5). The pure fractions were collected and the solvent was evaporated, yielding 48.5 g (70 %) of (±)-2-[[4-(trifluoromethyl)phenyl]methyl]-4-piperidinone (intermediate 19).

35 Example A.10

a) A mixture of ethyl β-oxobenzenebutanoate (0.5 mol) and benzenemethanamine (0.5 mol) in toluene (500 ml) was hydrogenated at 120°C (pressure = 100 kg) overnight in the presence of Cu₂Cr₂O₅ (5 g) and CuO (10 g). After uptake of hydrogen, the

catalyst was filtered off and the filtrate was evaporated, yielding 29.7 g of (±)-ethyl *N*,2-bis(phenylmethyl)-β-alanine (intermediate 20).

b) Ethyl chloroacetate (0.3 mol) was added to a mixture of intermediate 20 (0.2 mol) in DMF (250 ml). The mixture was stirred and triethylamine (0.4 mol) was added. The mixture was stirred at 60°C overnight. The solvent was evaporated and the residue was taken up in water/CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated, yielding 76.6 g of (±)-ethyl 3-[(2-ethoxy-2-oxoethyl)(phenylmethyl)amino]benzenebutanoate (intermediate 21).

c) Intermediate 21 (0.2 mol) was heated to 80°C under N₂ flow. NaOCH₃ (44 g) was added. The mixture was stirred at 80°C for 30 minutes. The solvent was evaporated and water (170 ml) and HCl (6N, 60 ml) were added. The mixture was stirred and refluxed for 1 hour, then cooled, alkalized with NaOH and extracted with CH₂Cl₂. The organic layer was separated, washed with water and a saturated NaCl solution, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃CN 100/0 to 96/4). The pure fractions were collected and the solvent was evaporated, yielding 7.8 g of (±)-1,5-bis(phenylmethyl)-3-pyrrolidinone (intermediate 22).

d) A mixture of intermediate 22 (0.027 mol) and CH₃SO₃H (0.03 mol) in THF (200 ml) was hydrogenated with palladium on activated carbon (10%, 2 g) as a catalyst. After uptake of hydrogen, the catalyst was filtered off, yielding (±)-5-(phenylmethyl)-3-pyrrolidinone methanesulfonate(1:1) (intermediate 23).

e) 3,5-di(trifluoromethyl)benzoyl chloride (0.03 mol) was added to intermediate 23 (0.027 mol). The mixture was stirred and triethylamine (0.1 mol) was added. The mixture was stirred at RT for 18 hours and then washed with water, NaOH and a saturated NaCl solution. The organic layer was separated, washed with a saturated NaCl solution, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 98/2). The pure fractions were collected and the solvent was evaporated, yielding 1.4 g of (±)-1-[3,5-bis(trifluoromethyl)benzoyl]-5-(phenylmethyl)-3-pyrrolidinone (intermediate 24).

B. Preparation of the compounds of formula (I)

Example B.1

a) Titanium(IV)isopropoxide (16.5 g) was added to a mixture of intermediate 3 (21.5 g) and 1-(phenylmethyl)piperazine (8.81 g) in DCM (35 ml). The mixture was stirred for 3 hours at RT. Sodium cyanoborohydride (2.85 g) and ethanol (70 ml) were added and the resulting reaction mixture was stirred overnight at RT. Water (5 ml) and DCM were added. The biphasic mixture was filtered over dicalite, and the filter residue was washed

with DCM. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was crystallized from CH₃CN and the precipitate was filtered off and dried, yielding 7.93 g (26.9 %) of (±)-*cis*-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-[4-(phenylmethyl)-1-piperazinyl]piperidine (compound 16; mp. 143.8 °C).

b) The mother liquor was concentrated and the residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 100/0, then 99/1, 98/2, 97/3). The desired fractions ((A) and (B)) were collected and their solvent was evaporated. The A-isomer was crystallized from CH₃CN, filtered off and dried, yielding 1.11 g (4 %) of compound 16. The pure fractions of the B-isomer were concentrated, yielding 5.9 g (20%) of (±)-*trans*-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-[4-(phenylmethyl)-1-piperazinyl]piperidine. The impure fractions of the B-isomer were collected and the solvent was evaporated. The residue was converted into the fumaric acid salt (1:2) in ethanol. The precipitate was filtered off and dried, yielding 1.89 g (±)-*trans*-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-[4-(phenylmethyl)-1-piperazinyl]piperidine (E)-2-butenedioate(1:2) (compound 17; mp. 240.3 °C).

Example B.2

A mixture of compound 16 (8.4 g) in methanol (250 ml) was hydrogenated at 50 °C with palladium on activated carbon (10 %) (2 g) as a catalyst. After uptake of H₂, the catalyst was filtered off and the filtrate was evaporated, yielding 7 g (100 %) of (±)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-(1-piperazinyl)piperidine (compound 15).

Example B.3

a) Titanium(IV)isopropoxide (13.2 g) was added to a mixture of intermediate 3 (17.16 g) and *N*-(2,6-dimethylphenyl)-1-piperazineacetamide (9.88 g) in DCM (20 ml). This mixture was stirred for 3 hours at RT. Sodium cyanoborohydride (2.52 g) in ethanol (20 ml) was added and the resulting reaction mixture was stirred overnight at RT. Water (10 ml) was added and the reaction mixture was extracted with DCM (800 ml). The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was taken up into water and this mixture was extracted with DCM. The separated organic layer was dried, filtered, and the solvent evaporated. The residue was pre-purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH 97/3). The desired fractions were collected and the solvent was evaporated, giving 4 g of the *trans*-racemate. Resolution was obtained by purification over stationary phase Chiralcel OD (eluent: CH₃OH 100%). Two desired *trans*-fraction groups were collected and their solvent was evaporated, yielding 1.75 g fraction 1 and 2 g fraction 2. Fraction 1 was dissolved in DCM, filtered and the filtrate was evaporated. The residue was dried,

- yielding 1.55 g (6%) (-)-(A)-*trans*-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide (compound 26; mp. 97.4 °C; $[\alpha]_D^{20} = -5.81^\circ$ (c = 1 % in DMF)). Fraction 2 was dissolved in DCM, filtered and the filtrate was evaporated. The residue was dried, yielding 1.70 g (6%) (+)-
- 5 (B)-*trans*-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide (compound 27; mp. 96.8 °C; $[\alpha]_D^{20} = +5.71^\circ$ (c = 1 % in DMF)).
- b) Compound 27 was dissolved in warm 2-propanol and converted into the (L)-malic acid salt with a solution of (L)-malic acid in 2-propanol. The mixture was stirred for
- 10 2 hours and the precipitate was filtered off and dried, yielding (+)-(B)-*trans*-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide (L)-malic acid (1:1) (compound 95).

Example B.4

- 15 A mixture of compound 15 (2.5 g), intermediate 5 (1.65 g) and sodium carbonate (0.64 g) in methylisobutylketone (50 ml) was stirred and refluxed for 3 hours. The reaction mixture was washed and the separated organic layer was dried, filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent: CH₂Cl₂/CH₃OH 100/0 and 99.5/0.5). The pure fractions were collected and the solvent
- 20 was evaporated, yielding 1.59 g (43%) of (±)-3,5-dimethylphenyl *cis*-4-[1-[3,5-bis-(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-α-phenyl-1-piperazineacetate (compound 43; mp. 88.1 °C).

Example B.5

- 25 A mixture of intermediate 2 (3.2 g), 1-(diphenylmethyl)piperazine (2.5 g) and aluminum tributoxide (2 g) in toluene (250 ml) was hydrogenated for 48 hours at 50 °C, with palladium on activated carbon (10 %; 2 g) as a catalyst in the presence of thiophene (4 % solution; 1 ml). After uptake of hydrogen (1 equiv), the catalyst was filtered off and the filtrate was evaporated. The residue was purified by high-performance liquid
- 30 chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 100/0, upgrading to 90/10). Two pure fractions were collected and their solvent was evaporated, resulting in residue 1 and residue 2. Residue 1 was suspended in DIPE. The precipitate was filtered off and dried, yielding 0.94 g (17%) of (±)-*cis*-1-(dimethylbenzoyl)-4-[4-(diphenylmethyl)-1-piperazinyl]-2-(phenylmethyl)piperidine (compound 12; mp. 100.8 °C). Residue 2 was
- 35 dried, yielding 0.2 g (3.6%) of (±)-*trans*-1-(dimethylbenzoyl)-4-[4-(diphenylmethyl)-1-piperazinyl]-2-(phenylmethyl)piperidine (compound 13).

Example B.6

A mixture of compound 15 (0.005 mol) and 1,2-epoxyethylbenzene (0.006 mol) in methanol (50 ml) was stirred at RT for 1 hour. The mixture was stirred and refluxed for 3 hours. The solvent was evaporated and the residue was purified over silica gel on a glass filter (eluent: CH₂Cl₂/CH₃OH 100/0, 99/1 and 98/2). The pure fractions were collected and the solvent was evaporated. The residue was purified by HPLC over silica gel (eluent: CH₂Cl₂/CH₃OH 98/2 to 95/5). Two pure fractions were collected and their solvents were evaporated. Each residue was dried, yielding 0.7 g (23%) of (±)-*cis*-1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-(2-hydroxy-2-phenylethyl)-1-piperazinyl]-2-(phenylmethyl)piperidine (compound 60) and 0.23 g (7%) of (±)-*cis*-1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-(2-hydroxy-1-phenylethyl)-1-piperazinyl]-2-(phenylmethyl)piperidine (compound 61).

Example B.7

Compound 15 (0.005 mol), 2-chloro-1-[(2-methyl-5-oxazolyl)methyl]-1*H*-benzimidazole (0.005 mol) and Copper (0.005 mol) were stirred at 140°C for 2 hours. The mixture was cooled, dissolved in CH₂Cl₂, filtered and washed with CH₂Cl₂ and a diluted NH₄OH solution. The organic layer was separated, washed with a diluted NH₄OH solution, dried, filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent: CH₂Cl₂/CH₃OH 100/0, 99.5/0.5, 99/1, 98.5/1.5 and 98/2). The pure fractions were collected and the solvent was evaporated. The residue was dried, yielding 1.42 g (40%) (±)-*cis*-1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-[1-[(2-methyl-5-oxazolyl)methyl]-1*H*-benzimidazol-2-yl]-1-piperazinyl]-2-(phenylmethyl)piperidine (compound 70).

Example B.8

A mixture of intermediate 7 (0.0033 mol) and 3,5-dimethylbenzoyl chloride (0.0035 mol) in DCM (50 ml) was stirred at RT for 15 minutes. Triethylamine (0.007 mol) was added and the mixture was stirred at RT for 1 hour. Water was added. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was converted into the fumaric acid salt (1:1) with 2-propanol. The precipitate was filtered off and dried. The residue was converted into the free base with NaOH. The precipitate was filtered off and dried. The residue was purified over silica gel on a glass filter (eluent: CH₂Cl₂/CH₃OH 100/0, 99.5/0.5, 99/1, 98/2 and 97/3). The pure fractions were collected and the solvent was evaporated. The residue was dried, yielding 0.8 g (36%) (±)-*cis*-*N*-[2-[4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-1-piperazinyl]ethyl]-3,5-dimethylbenzamide (compound 116).

Example B.9

A mixture of compound 74, prepared according to example B.4, (0.004 mol) in methanol (150 ml) was hydrogenated at 50°C with palladium on activated carbon (10 %; 1 g) as a catalyst in the presence of thiophene (4 % solution, 1ml). After uptake of hydrogen, the catalyst was filtered off and the filtrate was evaporated. The residue was crystallized from DIPE. The precipitate was filtered off, washed with DIPE and dried. This fraction was dissolved in toluene. The mixture was filtered and the solvent was evaporated. The residue was suspended in DIPE. The precipitate was filtered off and dried. This fraction was converted into the fumaric acid salt (1:2) with a warm solution of fumaric acid (0.52g) in ethanol. The mixture was stirred for 6 hours. The precipitate was filtered off and dried, yielding 0.91 g (25%) of (±)-*cis*-*N*-(4-amino-2,6-dimethylphenyl)-4-[1-[3,5-(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-1-piperazineacetamide (E)-2-butenedioate(1:2) (compound 129).

Example B.10

Sec-butyllithium (0.055 mol) was added at -78°C under N₂ flow to a solution of 1,1-dimethylethyl 4-(4-methyl-1-piperazinyl)-1-piperidinecarboxylate (0.05 mol) and *N,N,N',N'*-tetramethylethylenediamine (0.1 mol) in (C₂H₅)₂O (50 ml). 2 hours after complete addition, a mixture of benzaldehyde (0.05 mol) in (C₂H₅)₂O (50 ml) was added. The mixture was allowed to warm to RT and then stirred at 25°C for 16 hours. The solvent was evaporated and the residue was washed with a saturated NH₄Cl solution and extracted with CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated. A solution of 2-methyl-2-propanol, potassium salt (0.02 mol) in toluene (100 ml) was added to this fraction and the mixture was stirred at 100°C for 2 hours. The solvent was evaporated. The residue was washed with a saturated NH₄Cl solution, extracted with CH₂Cl₂ and decanted. The organic layer was dried, filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent: CH₂Cl₂/CH₃OH 95/5). The pure fractions were collected and the solvent was evaporated. This fraction was dissolved in methanol (150 ml) and hydrogenated with palladium on activated carbon (10%, 3g) as a catalyst. After uptake of hydrogen, the catalyst was filtered off and the filtrate was evaporated. The residue was purified over silica gel on a glass filter (eluent: CH₂Cl₂/CH₃OH 95/5). The pure fractions were collected and the solvent was evaporated. This fraction was dissolved in DCM (20 ml) and Triethylamine (2 ml). 3,5-di(trifluoromethyl)benzoyl chloride (0.0087 mol) was added at 0°C. 1 hour after complete addition, water was added and the mixture was extracted with CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent:

CH₂Cl₂/CH₃OH 95/5). The pure fractions were collected and the solvent was evaporated. This fraction was converted into the (E)-2-butenedioic acid salt (1:2) with ethanol. The precipitate was filtered off and dried, yielding 4.7 g (74%) of (±)-*cis*-1-[3,5-bis(trifluoromethyl)benzoyl]-4-(4-methyl-1-piperazinyl)-2-(phenylmethyl)piperidine (E)-2-butenedioate(1:2) (compound 130).

Example B.11

A mixture of compound 15 (0.005 mol), *N*-[2-(3,4-dichlorophenyl)-4-[(methylsulfonyl)oxy]butyl]-*N*-methyl benzamide (0.0055 mol) and NaHCO₃ (0.0055 mol) in ethanol (50 ml) was stirred and refluxed for 6 hours. The solvent was evaporated, the residue was taken up in water and extracted with CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent: CH₂Cl₂/CH₃OH 100/0, 99/1, 98/2 and 97/3). The pure fractions were collected and the solvent was evaporated. The residue was converted into the fumaric acid salt (1:2) with ethanol. The precipitate was filtered off and dried, yielding 1.42 g (27%) of (±)-*cis*-*N*-[4-[4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-1-piperazinyl]-2-(3,4-dichlorophenyl)butyl]-*N*-methylbenzamide (E)-2-butenedioate(1:2) (compound 93).

Example B.12

A mixture of (±)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,5-difluorophenyl)methyl]-4-piperidinone (0.0058 mol), *N*-(2,6-dimethylphenyl)-1-piperazineacetamide (0.0058 mol) and titanium(IV)isopropoxide (0.0064 mol) in 2-propanol (5 ml) was stirred at RT overnight. NaBH₄ (0.0116 mol) and ethanol (15 ml) were added. The mixture was stirred for 2 days. Water (5 ml) was added and the mixture was stirred for 10 minutes. CH₂Cl₂ (200 ml) was added. The organic layer was separated, dried, filtered and the solvent was evaporated. This fraction was purified by HPLC over silica gel (eluent: CH₂Cl₂/CH₃OH 98/2 to 90/10 over a 30-minute period). Two pure fractions (F1 and F2) were collected and their solvents were evaporated. F1 was purified by column chromatography over RP18 (eluent: NH₄OAc (0.5% in H₂O)/CH₃CN 40/60). The pure fractions were collected and the solvent was evaporated. The residue was dried, yielding 0.33 g (8%) of (±)-*cis*-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,5-difluorophenyl)methyl]-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazineacetamide (compound 132). F2 was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 100/0 to 92/8 over a 30-minute period). The pure fractions were collected and the solvent was evaporated. The residue was dissolved in CH₂Cl₂, filtered and the solvent was evaporated. The residue was dried, yielding 0.24 g (6%) of (±)-*trans*-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,5-difluorophenyl)methyl]-4-piperidinyl]-*N*-

(2,6-dimethylphenyl)-1-piperazineacetamide (compound 133).

Example B.13

3,5 di(trifluoromethyl)benzoyl chloride (0.0011 mol) was added to a mixture of (\pm)-*trans*-
5 4-[2-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine-
acetamide (0.001 mol) in DCM (20ml). The mixture was stirred for 5 minutes. Triethyl-
amine (2ml) was added. The mixture was stirred at RT for 3 hours, washed with a
diluted NaOH solution and with water, and then dried. The solvent was evaporated.
The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/
10 CH₃OH 96/4). The pure fractions were collected and the solvent was evaporated. The
residue was crystallized from CH₃CN. The precipitate was filtered off and dried,
yielding 0.32 g (44%) of (\pm)-*trans*-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-
dichlorophenyl)methyl]-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazineacetamide
15 (compound 139).

Example B.14

A mixture of compound 15 (0.01 mol) and imidazo[1,2-a]pyridin-2-carboxaldehyde
(0.01 mol) in methanol (250 ml) was hydrogenated at RT overnight with palladium on
activated carbon (10%, 2 g) as a catalyst in the presence of thiophene (4% solution,
20 2 ml). After uptake of hydrogen, the catalyst was filtered off and the filtrate was
evaporated. The residue was purified over silica gel on a glass filter (eluent : CH₂Cl₂/
CH₃OH 100/0, 99/1, 98/2, 97/3 and 96/4). The pure fractions were collected and the
solvent was evaporated. The residue was converted into the fumaric acid salt (1:2) from
ethanol. The precipitate was filtered off and dried, yielding 2.8 g (32%) of
25 (\pm)-*cis*-1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-(imidazo[1,2-a]pyridin-2-ylmethyl)-1-
piperazinyl]-2-(phenylmethyl)piperidine (E)-2-butenedioate(1:2) (compound 111).

Example B.15

(+)-(B-*trans*)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-*N*-
30 (2,6-dimethylphenyl)-1-piperazineacetamide (0.003 mol) was dissolved in ethanol
(20 ml). A solution of fumaric acid (0.003 mol) in ethanol (15 ml) was added and the
mixture was stood for 7 days. The precipitate was filtered off and dried, yielding 1.2 g
of (B-*trans*)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-*N*-
(2,6-dimethylphenyl)-1-piperazineacetamide (E)-2-butenedioate(1:1) (compound 128).
35

Example B.16

A mixture of (\pm)-1-[3,5-bis(trifluoromethyl)benzoyl]-5-(phenylmethyl)-3-pyrrolidinone
(0.0037 mol) and *N*-(2,6-dimethylphenyl)-1-piperazineacetamide (0.0037 mol) in

methanol (150 ml) was hydrogenated at 50°C with palladium on activated carbon (10%, 1 g) as a catalyst in the presence of thiophene solution (1 ml). After uptake of hydrogen, the catalyst was filtered off and the filtrate was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 95/5). The desired
5 fractions were collected and the solvent was evaporated. The residue was dried and then crystallized from DIPE. The precipitate was filtered off and dried, yielding 0.35 g (15 %) of (±)-*cis*-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-5-(phenylmethyl)-3-pyrrolidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazineacetamide (compound 131).

10 Example B.17

(±)-*cis*-1-(phenylmethyl)-4-[2-(phenylmethyl)-1-piperidinyl]piperazine (0.00043 mol) was added to 3,4-dichlorobenzeneacetic acid (± 0.0004 mol) and 1-hydroxybenzotriazole hydrate (0.080 g) in DCM (5 ml). The mixture was stirred and cooled on an ice/ethanol-bath, under N₂ flow. Triethylamine was added dropwise. A solution of 1-(3-dimethyl-
15 aminopropyl)-3-ethylcarbodiimide hydrochloride (0.120 g) in DCM (5 ml) was added and the reaction mixture was allowed to warm to RT, under N₂. The reaction mixture was stirred overnight. The mixture was diluted with CH₂Cl₂, until a 15-ml total volume was obtained. Then, the compound was isolated and purified by HPLC over silica gel (eluent: CH₂Cl₂ to CH₂Cl₂/CH₃OH 90/10 over 20 minutes at 125 ml/minute). The
20 desired fractions were collected and the solvent was evaporated, yielding 0.020 g of (±)-*cis*-1-[(3,4-dichlorophenyl)acetyl]-2-(phenylmethyl)-4-[4-(phenylmethyl)-1-piperazinyl]piperidine (compound 181).

Example B.18

25 3,5-di(trifluoromethyl)-1-isocyanatobenzene (0.0025 mol) in DCM (10 ml) was added to a mixture of (±)-*trans*-*N*-(2,6-dimethylphenyl)-4-[2-(phenylmethyl)-4-piperidinyl]-1-piperazineacetamide (0.0025 mol) in DCM (15 ml). The mixture was stirred at RT overnight. The precipitate was filtered off and dried, yielding 0.66 g (40%) of (±)-*trans*-
4-[1-[[[3,5-bis(trifluoromethyl)phenyl]amino]carbonyl]-2-(phenylmethyl)-4-piperidinyl]-
30 *N*-(2,6-dimethylphenyl)-1-piperazineacetamide (compound 143).


Example B.19

A mixture of (±)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-4-piperidinone (0.01 mol) and *N*-(2,6-dimethylphenyl)-1-piperazine-
35 acetamide (0.01 mol) in 2-propanol (150 ml) was hydrogenated at 50°C with platinum on activated carbon (5 %; 2 g) as a catalyst in the presence of titanium(IV)isopropoxide (2.84 g) and thiophene solution (1 ml). After uptake of hydrogen, the catalyst was filtered off and the filtrate was evaporated. The residue was taken up in CH₂Cl₂ and H₂O. The

organic layer was separated, washed several times with H₂O, dried, filtered over dicalite and the solvent was evaporated. This fraction was purified by HPLC over silica gel (eluent: CH₂Cl₂/CH₃OH 98/2). Two pure fractions were collected and their solvents were evaporated. The residue was dried, yielding 0.72 g (10 %) of (±)-*cis*-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-4-piperidiny]-*N*-(2,6-dimethylphenyl)-1-piperazineacetamide (compound 140) and 0.88 g (12 %) of (±)-*trans*-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-4-piperidiny]-*N*-(2,6-dimethylphenyl)-1-piperazineacetamide (compound 141).

Tables 1 to 4 list compounds of formula (I) that were prepared according to one or more of the foregoing examples (Ex.).


Table 1



Co. No.	Ex.	-L	Physical data (mp = melting point)
1	6	-H	(±)- <i>cis</i>
2	6	-H	(±)- <i>trans</i>
3	9		(±)- <i>cis</i> ; mp 196.9 °C
4	9		(±)- <i>trans</i>
5	5		(±)- <i>cis</i> ; mp 94.0 °C
6	5		(±)- <i>trans</i>
7	8		(±)- <i>cis</i> -(E) ; mp 201.0 °C












Co. No.	Ex.	-L	Physical data (mp = melting point)
8	8		(±)- <i>trans</i> -(E); mp 210.1 °C
9	8		(±)- <i>cis</i> ; mp 92.1 °C
10	9		(±)- <i>cis</i> ; mp 72.8 °C
11	9		(±)- <i>trans</i>
12	9		(±)- <i>cis</i> ; mp 100.8 °C
13	9		(±)- <i>trans</i>












Table 2














5











Co. No.	Ex.	n	p	-L	Physical data (mp = melting point)
14	B.2	1	1	-H	(±)- <i>trans</i>
15	B.2	1	1	-H	(±)- <i>cis</i>
16	B.1.a	1	1		(±)- <i>cis</i> ; mp 143.8 °C
17	B.1.a+b	1	1		(±)- <i>trans</i> ; mp 240.3 °C ; fumaric acid (1:2)










Co. No.	Ex.	n	p	-L	Physical data (mp = melting point)
18	B.1	1	1		(±)- <i>cis</i> ; mp 120°C
19	B.1	1	1		(±)- <i>trans</i> ; mp 150°C
20	B.1	1	1		(±)- <i>cis</i> ; mp 70.4°C
21	B.1	1	1		(±)- <i>trans</i> ; mp 169.1°C
22	B.1	1	1		(±)- <i>trans</i> ; mp 173.8°C
23	B.1	1	1		(±)- <i>cis</i> ; mp 93.2°C
24	B.1	1	1		(±)- <i>trans</i> ; mp 100.1°C
25	B.1	1	1		(±)- <i>trans</i> ; mp 75.4°C
26	B.1 and B.3	1	1		(-)-(A)- <i>trans</i> ; mp 97.4°C; [α] _D ²⁰ = -5.81° (c = 1 % in DMF)
27	B.1 and B.3	1	1		(+)-(B)- <i>trans</i> ; mp 96.8°C; [α] _D ²⁰ = +5.71° (c = 1 % in DMF)
28	B.1	1	1		(±)- <i>cis</i> ; (E)










Co. No.	Ex.	n	p	-L	Physical data (mp = melting point)
29	B.1	1	1		(±)- <i>trans</i> ; (E)
30	B.1	1	1		(±)- <i>trans</i> ; mp 185.7°C
31	B.1	1	1		(±)- <i>cis</i> ; mp 77.5°C
32	B.1	1	1		(±)- <i>cis</i> ; mp 183.1°C
33	B.1	1	1		(±)- <i>trans</i> ; mp 115.6°C
34	B.1	1	2		(±)- <i>trans</i> ; mp 120.1°C
35	B.1	1	1		(±)- <i>cis</i> ; mp 150.9°C
36	B.1	1	1		(±)- <i>trans</i> ; mp 120.8°C
37	B.4	1	1		(±)- <i>cis</i> ; mp 85.6°C
38	B.4	1	1		(±)- <i>trans</i> ; mp 170.5°C
39	B.4	1	1	$\text{-CH}_2\text{-CH}_2\text{-OH}$	(±)- <i>cis</i> ; mp 192.9°C
40	B.4	1	1		(±)- <i>trans</i> ; mp 240.7°C

Co. No.	Ex.	n	p	-L	Physical data (mp = melting point)
41	B.4	1	1		(+)-(A)- <i>cis</i> ; mp 177.3°C; [α] _D ²⁰ = +19.88° (c = 1 % in methanol)
42	B.4	1	1		(-)-(B)- <i>cis</i> ; mp 177.3°C; [α] _D ²⁰ = -20.34° (c = 1 % in methanol)
43	B.4	1	1		(±)- <i>cis</i> ; mp 88.1°C
44	B.4	1	1		(±)- <i>cis</i> ; mp 227.1°C; fumaric acid (1:2)
45	B.4	1	1		(±)- <i>trans</i> ; mp 200.2°C
46	B.4	1	1		(±)- <i>trans</i> ; mp 105.6°C
47	B.4	1	1		(±)- <i>cis</i> ; mp 89.2°C
48	B.1	1	1		(±)- <i>trans</i> ; mp 89.7°C
49	B.1	1	1		(±)- <i>cis</i> ; mp 135.8°C
50	B.4	1	1		(±)- <i>trans</i> ; mp 140.4°C












Co. No.	Ex.	n	p	-L	Physical data (mp = melting point)
51	B.4	1	1		(±)-cis; mp 173.5°C
52	B.4	1	1		(±)-cis; mp 101.5°C
53	B.4	1	1		(±)-trans; mp 185.8°C
54	B.5	1	1		(±)-cis; mp 260°C
55	B.5	1	1		(±)-trans; mp 75.2°C
56	B.5	1	1		(±)-trans; mp 80.1°C
57	B.5	1	1		(±)-cis
58	B.1	1	1		(±)
59	B.4	1	1		(±)-cis; mp 106.4°C
60	B.6	1	1		(±)-cis
61	B.6	1	1		(±)-cis










Co. No.	Ex.	n	p	-L	Physical data (mp = melting point)
62	B.1	1	1	$\text{CH}_2\text{-CH}_2\text{O-CH}_2\text{CH}_3$ 	(±)-cis
63	B.1	1	2		(±)-cis; fumaric acid (1:2)
64	B.2	1	2	-H	(±)-cis
65	B.4	1	2		(±)-cis
66	B.1	1	1		(±)-cis
67	B.1	1	1		(±)-trans
68	B.1	1	2		(±)-trans; fumaric acid (1:2)
69	B.4	1	1		(±)-trans
70	B.7	1	1		(±)-cis
71	B.4	1	1		(±)-cis
72	B.4	1	1		(±)-cis

Co. No.	Ex.	n	p	-L	Physical data (mp = melting point)
73	B.4	1	1		(±)-cis; fumaric acid (1:2)
74	B.4	1	1		(±)-cis
75	B.4	1	1		(±)-cis; fumaric acid (1:1)
76	B.4	1	1	$-\text{CH}_2-\text{C}(=\text{O})-\text{NH}-\text{CH}(\text{CH}_3)_2$	(±)-cis
77	B.2	1	2	-H	(±)-trans
78	B.4	1	2		(±)-trans
79	B.8	1	1		(±)-cis
80	B.1	1	1		(+)-(B)-trans
81	B.2	1	1	-H	(+)-(B)-trans
82	B.1	1	1		(±)-cis
83	B.1	1	1		(±)-trans
84	B.4	1	1		(±)-cis

Co. No.	Ex.	n	p	-L	Physical data (mp = melting point)
85	B.7	1	1		(±)-trans
86	B.6	1	1		(±)-trans
87	B.1	1	1		(±)-trans
88	B.1	1	1		(±)-cis; fumaric acid (1:2)
89	B.4	1	1	$-(CH_2)_2-OH$	(±)-trans
90	B.11	1	1		(±)-trans; fumaric acid (1:2)
91	B.4	1	1		(±)-trans; fumaric acid (1:2)
92	B.11	1	1		(±)-trans
93	B.11	1	1		(±)-cis; fumaric acid (1:2)
94	B.4	1	1		(±)-trans


Co. No.	Ex.	n	p	-L	Physical data (mp = melting point)
95		1	1		(B)- <i>trans</i> ; (L)-malic acid (1:1)
96	B.4	1	1		(±)- <i>trans</i> ; fumaric acid (1:2)
97	B.4	1	1		(±)- <i>trans</i>
98	B.4	1	1		(±)- <i>cis</i>
99	B.4	1	1		(±)- <i>cis</i>
100	B.4	1	1		(±)- <i>cis</i>
101	B.4	1	1		(±)- <i>cis</i>
102	B.4	1	1		(±)- <i>cis</i>
103	B.4	1	1		(±)- <i>cis</i> fumaric acid (1:2)

Co. No.	Ex.	n	p	-L	Physical data (mp = melting point)
104	B.4	1	1		(±)- <i>trans</i>
105	B.4	1	1		(±)- <i>trans</i>
106	B.4	1	1		(±)- <i>trans</i>
107	B.4	1	1		(±)- <i>trans</i>
108	B.4	1	1		(±)- <i>trans</i>
109	B.4	1	1		(±)- <i>trans</i>
110	B.14	1	1		(±)- <i>trans</i> ; fumaric acid (1:2)
111	B.14	1	1		(±)- <i>cis</i> ; fumaric acid (1:2)
112	B.4	1	1		(±)- <i>trans</i>
113	B.1	1	1		(±)- <i>trans</i>
114	B.2	1	1	H	(±)- <i>trans</i> ; fumaric acid (1:2)
115	B.8	1	1		(±)- <i>trans</i>



Co. No.	Ex.	n	p	-L	Physical data (mp = melting point)
116	B.8	1	1		(±)- <i>cis</i>
117	B.8	1	1		(±)- <i>trans</i>
118	B.4	1	1		(±)- <i>trans</i> ; fumaric acid (1:2)
119	B.4	1	1		(±)- <i>trans</i>
120	B.13	1	1		(±)- <i>trans</i>
121	B.1	1	1		(±)- <i>cis</i>
122	B.1	1	1		(±)- <i>trans</i>
123	B.4	1	1		(±)- <i>cis</i>
124	B.15	1	1		(B)- <i>trans</i> ; benzoate (1:1)

Co. No.	Ex.	n	p	-L	Physical data (mp = melting point)
125	B.15	1	1		(B)- <i>trans</i> ; maleic acid (1:1)
126	B.15	1	1		(B)- <i>trans</i> ; hydrochloric acid (1:2) hydrate (1:1)
127	B.15	1	1		(B)- <i>trans</i> ; succinic acid (1:1)
128	B.15	1	1		(B)- <i>trans</i> ; fumaric acid (1:1)
129	B.9	1	1		(±)- <i>cis</i> ; fumaric acid (1:2)
130	B.10	1	1	-CH ₃	(±)- <i>cis</i> ; fumaric acid (1:2)
131	B.16	0	1		(±)- <i>cis</i>

Table 3




Co. No.	Ex.	X&	R ²	R _a	R _b	R _c	Physical data
132	B.12	c.b.	3,5-di(trifluoromethyl)phenyl	F	H	F	(±)- <i>cis</i>
133	B.12	c.b.	3,5-di(trifluoromethyl)phenyl	F	H	F	(±)- <i>trans</i>
134	B.12	c.b.	3,5-di(trifluoromethyl)phenyl	H	F	F	(±)- <i>cis</i>
135	B.12	c.b.	3,5-di(trifluoromethyl)phenyl	H	F	F	(±)- <i>trans</i>
136	B.4	c.b.	3,5-di(trifluoromethyl)phenyl	H	CF ₃	H	(±)-(B) fumaric acid (1:1)
137	B.4	c.b.	3,5-di(trifluoromethyl)phenyl	H	CF ₃	H	(±)-(A)
138	B.13	c.b.	3,5-di(trifluoromethyl)phenyl	H	Cl	Cl	(±)- <i>cis</i>
139	B.13	c.b.	3,5-di(trifluoromethyl)phenyl	H	Cl	Cl	(±)- <i>trans</i>
140	B.19	c.b.	3,5-di(trifluoromethyl)phenyl	F	H	CF ₃	(±)- <i>cis</i>
141	B.19	c.b.	3,5-di(trifluoromethyl)phenyl	F	H	CF ₃	(±)- <i>trans</i>
142	B.13	c.b.	3-isopropoxyphenyl	H	H	H	(±)- <i>cis</i>
143	B.18	-NH-	3,5-di(trifluoromethyl)phenyl	H	H	H	(±)- <i>trans</i>
144	B.13	c.b.	phenyl	H	H	H	(±)- <i>cis</i>
145	B.13	c.b.	2-naphthyl	H	H	H	(±)- <i>trans</i>
146	B.13	c.b.	2-quinoliny	H	H	H	(±)- <i>trans</i>
147	B.13	c.b.	2-quinoxaliny	H	H	H	(±)- <i>trans</i>
148	B.13	-O-	benzyl	H	H	H	(±)- <i>trans</i>
149	B.17	c.b.	3-methyl-benzofuran-2-yl	H	H	H	(±)- <i>trans</i>
150	B.17	c.b.	5-fluoro-indol-2-yl	H	H	H	(±)- <i>trans</i>
151	B.17	c.b.	5-indolyl	H	H	H	(±)- <i>trans</i>
152	B.17	c.b.	5-methyl-pyrazin-2-yl	H	H	H	(±)- <i>trans</i>
153	B.13	c.b.	phenyl	H	H	H	(±)- <i>trans</i>




Co. No.	Ex.	X&	R ²	R _a	R _b	R _c	Physical data
154	B.13	c.b.	5-methyl-isoxazol-3-yl	H	H	H	(±)- <i>trans</i>
155	B.13	c.b.	2,4,6-trimethylphenyl	H	H	H	(±)- <i>cis</i>
156	B.13	c.b.	3,4,5-trimethoxyphenyl	H	H	H	(±)- <i>cis</i>
157	B.13	c.b.	3-cyanophenyl	H	H	H	(±)- <i>cis</i>
158	B.13	c.b.		H	H	H	(±)- <i>cis</i>
159	B.13	c.b.	3,5-difluorophenyl	H	H	H	(±)- <i>cis</i>
160	B.13	c.b.	2,6-dichloro-pyridin-4-yl	H	H	H	(±)- <i>cis</i>
161	B.13	c.b.	2-naphthyl	H	H	H	(±)- <i>cis</i>
162	B.13	c.b.	2-quinoliny	H	H	H	(±)- <i>cis</i>
163	B.13	c.b.	3-isopropoxybenzyl	H	H	H	(±)- <i>cis</i>
164	B.13	c.b.	1-phenylethyl	H	H	H	(±)- <i>cis</i>
165	B.13	c.b.	3-isopropoxyphenyl	H	H	H	(±)- <i>trans</i>
166	B.13	c.b.	3-cyanophenyl	H	H	H	(±)- <i>trans</i>
167	B.13	c.b.		H	H	H	(±)- <i>trans</i>
168	B.13	c.b.	2,4-dichlorophenyl	H	H	H	(±)- <i>trans</i>
169	B.13	c.b.	2-thienyl	H	H	H	(±)- <i>trans</i>

& c.b. = covalent bond

Table 4

5



Co.No.	Ex.	R _a	X&	R ²	L	Physical data
170	B.1	CF ₃	c.b.	3,5-di(trifluoro-methyl)phenyl	H	(±)-(A)
171	B.1	CF ₃	c.b.	3,5-di(trifluoro-methyl)phenyl	H	(±)-(B) fumaric acid (1:4)
172	B.13	H	c.b.	3-trifluoromethyl-phenyl	benzyl	(±)- <i>cis</i>
173	B.13	H	c.b.	3,5-difluoro-phenyl	benzyl	(±)- <i>cis</i>
174	B.13	H	c.b.	2-naphtyl	benzyl	(±)- <i>cis</i>
175	B.13	H	c.b.	3-cyano-phenyl	benzyl	(±)- <i>cis</i>
176	B.13	H	-O-	benzyl	benzyl	(±)- <i>cis</i>
177	B.13	H	c.b.	2-furanyl	benzyl	(±)- <i>cis</i>
178	B.13	H	c.b.	2-thienyl	benzyl	(±)- <i>cis</i>
179	B.13	H	c.b.	phenyl	benzyl	(±)- <i>cis</i>
180	B.13	H	c.b.	3,5-dichloro-phenyl	benzyl	(±)- <i>cis</i>
181	B.17	H	c.b.	3,4-dichlorophenyl	benzyl	(±)- <i>cis</i>
182	B.13	H	c.b.		benzyl	(±)- <i>cis</i>
183	B.13	H	c.b.	phenyl	benzyl	(±)- <i>trans</i>
184	B.13	H	c.b.	2,6-dichloro-pyridin-4-yl	benzyl	(±)- <i>trans</i>
185	B.13	H	c.b.	2-furanyl	benzyl	(±)- <i>trans</i>
186	B.13	H	c.b.	2-thienyl	benzyl	(±)- <i>trans</i>
187	B.13	H	c.b.	3-cyano-phenyl	benzyl	(±)- <i>trans</i>
188	B.13	H	c.b.		benzyl	(±)- <i>trans</i>
189	B.13	H	c.b.		benzyl	(±)- <i>trans</i>
190	B.13	H	c.b.	5-methyl-isoxazol-3-yl	benzyl	(±)- <i>trans</i>
191	B.13	H	c.b.	2-nitrophenyl	benzyl	(±)- <i>cis</i>
192	B.16	H	c.b.	2-aminophenyl	benzyl	(±)- <i>cis</i> fumaric acid (1:2)

& c.b. = covalent bond

- 5 Table 5 lists both the experimental (column heading "Exp") and theoretical (column heading "Theor") elemental analysis values for carbon, hydrogen and nitrogen for the compounds as prepared in the experimental part hereinabove.

Table 5

Co. No.	C		H		N	
	Exp	Theor	Exp	Theor	Exp	Theor
5	75.47	76.05	8.06	8.02	9.91	10.14
6	75.08	76.05	8.18	8.02	10.02	10.14
7	68.40	68.18	6.68	6.68	5.52	5.68
8	67.39	68.18	6.83	6.68	5.62	5.68
9	71.98	71.77	7.59	7.40	7.11	7.17
10	76.99	77.23	8.12	7.90	8.16	8.44
12	81.31	81.83	7.79	7.77	7.36	7.53
16	64.88	65.19	5.53	5.64	7.05	7.13
17	58.45	58.46	4.85	5.03	5.01	5.11
19	61.61	61.91	5.03	5.35	10.32	10.62
20	60.51	60.71	4.92	4.92	6.89	7.08
21	60.74	60.71	4.86	4.92	7.02	7.08
22	63.09	62.87	5.56	5.72	10.08	10.18
23	62.68	62.98	5.21	5.28	11.43	11.60
24	62.44	62.98	5.18	5.28	11.33	11.60
25	60.33	61.53	5.42	5.74	11.62	11.96
26	63.42	63.63	5.96	5.80	8.52	8.48
27	63.41	63.63	5.82	5.80	8.04	8.48
30	63.02	62.94	5.19	5.28	7.01	7.10
31	62.68	62.94	5.31	5.28	7.08	7.10
32	66.40	66.47	5.44	5.58	7.66	7.75
33	66.42	66.47	5.60	5.58	7.55	7.75
34	62.07	62.98	5.10	5.28	11.46	11.60
35	65.11	65.04	5.08	5.03	5.89	5.99
36	64.94	65.04	4.97	5.03	6.03	5.99
37	62.58	62.65	5.26	5.42	8.63	8.86
38	60.87	61.62	5.22	5.48	8.23	8.45
40	62.28	62.43	4.78	5.08	11.28	11.38
41	63.44	63.63	5.69	5.80	8.36	8.48
42	63.83	63.63	5.77	5.80	8.40	8.48
43	66.54	66.75	5.52	5.60	5.61	5.70
45	56.47	56.50	4.40	4.60	7.89	7.99
46	64.49	64.71	5.77	5.87	7.92	8.16

Co. No.	C		H		N	
	Exp	Theor	Exp	Theor	Exp	Theor
47	63.46	63.63	5.84	5.80	8.39	8.48
48	65.16	65.53	6.38	6.20	7.71	7.84
49	65.43	65.53	6.25	6.20	7.81	7.84
50	63.71	63.63	5.64	5.80	8.40	8.48
51	61.79	61.62	5.46	5.48	8.31	8.45
52	64.50	64.71	5.70	5.87	7.92	8.16
53	63.77	63.63	5.90	5.80	8.25	8.48
54	63.54	64.53	5.15	5.29	5.19	5.37
55	67.97	68.56	5.65	5.60	6.02	6.31
56	63.34	63.46	5.39	5.49	6.79	6.94
57	63.54	63.46	5.43	5.49	6.97	6.94
59	63.58	63.63	5.75	5.80	8.37	8.48
60	64.13	63.97	5.61	5.69	6.60	6.78
61	63.41	63.97	5.65	5.69	6.60	6.78
62	62.65	62.87	5.76	5.72	9.97	10.18
63	58.77	58.92	5.14	5.19	4.99	5.03
65	63.78	64.08	6.24	5.98	7.97	8.30
66	62.89	64.22	5.41	5.39	11.03	10.96
67	63.06	64.22	5.18	5.39	10.62	10.96
69	60.74	61.28	5.57	5.68	11.15	11.28
70	62.34	62.53	4.81	5.11	11.62	11.82
71	54.59	54.69	4.03	4.20	7.04	7.29
72	59.45	59.57	5.01	5.28	9.71	9.92
74	54.84	54.85	4.18	4.47	9.28	9.41
76	59.66	60.19	6.21	6.06	8.93	9.36
78	63.95	64.08	5.90	5.98	8.23	8.30
79	55.18	55.25	4.08	4.38	7.04	7.16
82	62.65	63.63	5.80	5.80	8.22	8.48
83	61.84	63.63	5.91	5.80	8.00	8.48
84	58.20	58.49	5.21	5.38	12.81	13.20
85	61.55	62.53	5.15	5.11	11.53	11.82
86	63.82	63.97	5.58	5.69	6.73	6.78
87	67.38	68.37	5.48	6.15	5.48	5.70
92	61.87	61.95	5.17	5.32	6.32	6.72
93	57.14	57.47	4.71	4.92	5.02	5.26

Co. No.	C		H		N	
	Exp	Theor	Exp	Theor	Exp	Theor
94	66.62	66.84	5.55	5.75	7.23	7.60
95	58.94	58.94	5.60	5.58	6.97	7.05
96	52.25	52.35	4.82	4.97	11.15	11.25
97	62.54	62.35	5.26	5.37	11.64	11.79
98	63.86	63.82	5.30	5.51	8.39	8.51
99	64.29	64.28	5.40	5.69	8.17	8.33
100	62.13	62.35	5.16	5.37	11.59	11.79
101	64.49	64.28	5.68	5.69	8.08	8.33
102	67.17	66.84	5.82	5.75	7.36	7.60
103	58.42	58.69	5.39	5.47	6.15	6.08
104	64.16	64.28	5.73	5.69	8.31	8.33
105	63.95	64.08	6.01	5.98	8.25	8.30
106	62.27	62.65	5.37	5.42	8.84	8.86
107	63.76	63.82	5.54	5.51	8.45	8.51
108	54.46	54.69	4.08	4.20	7.20	7.29
109	58.46	58.49	5.19	5.38	12.90	13.20
110	56.57	57.14	4.58	4.80	7.96	8.13
111	56.80	57.14	4.59	4.80	7.99	8.13
112	56.42	56.33	4.73	4.88	10.77	10.95
114	54.52	54.17	4.61	4.82	5.75	5.74
115	64.06	64.08	6.07	5.98	8.16	8.30
116	63.87	64.08	5.89	5.98	8.11	8.30
117	55.13	55.25	4.18	4.38	7.05	7.16
118	57.96	58.41	4.90	5.12	6.06	6.19
119	60.60	60.60	5.45	5.42	9.12	9.42
120	59.92	59.72	4.73	4.70	6.20	6.53
121	63.51	63.82	5.60	5.51	8.43	8.51
122	63.53	63.82	5.77	5.51	9.05	8.51
123	64.81	65.00	5.75	5.75	10.17	10.24
131	63.23	63.15	5.72	5.61	8.51	8.66
132	60.00	60.34	4.90	5.21	7.76	8.04
133	59.93	60.34	5.17	5.21	7.94	8.04
134	60.22	60.34	5.22	5.21	7.94	8.04
135	60.87	60.34	5.44	5.21	7.97	8.04
137	59.04	59.34	5.01	5.12	7.43	7.69

Co. No.	C		H		N	
	Exp	Theor	Exp	Theor	Exp	Theor
138	57.81	57.62	4.76	4.97	7.54	7.68
139	57.28	57.62	4.73	4.97	7.25	7.68
140	57.53	57.91	4.88	4.86	7.18	7.50
141	57.45	57.91	4.79	4.86	7.21	7.50
142	73.32	74.19	8.25	7.96	9.28	9.61
143	61.66	62.21	5.77	5.82	10.21	10.36
144	75.31	75.54	7.76	7.68	10.28	10.68
145	76.49	77.32	7.43	7.37	9.33	9.75
170	53.73	55.03	4.46	4.62	7.14	7.40
192	64.48	65.13	6.20	6.33	7.84	7.99

C. Pharmacological example

Example C.1 : Antagonism of substance-P induced relaxation of the pig coronary arteries

- 5 Segments of coronary arteries taken from pigs (killed by injection of an overdose of sodium pentobarbital) were inverted and mounted for recording of isometric tension in organ baths (volume 20 ml) with the endothelium at the outside. The preparations were bathed in Krebs - Henseleit solution. The solution was kept at 37 °C and gassed with a mixture of O₂ / CO₂ (95/5). After stabilisation of the preparations, prostaglandin F_{2α}
- 10 (10⁻⁵ M) was administered to induce a contraction. This was repeated until contractile responses became stable. Then prostaglandin F_{2α} was again administered and substance P (3x10⁻¹⁰ M and 10⁻⁹ M cumulatively) was added. Substance P induced endothelium dependent relaxations. After washing away the agonists, a known concentration of a compound of formula (I) was added. After an incubation period of 30 minutes,
- 15 prostaglandin F_{2α} (10⁻⁵ M) and the same concentrations of substance P as described above were again administered in the presence of the compound to be tested. Relaxations caused by substance P were expressed as relaxations under control conditions, and percent inhibition of the response to 10⁻⁹ M substance P was taken as a measure of the antagonistic activity of the compound to be tested. Table 6 lists the IC₅₀ values
- 20 (concentration at which 50 % of the response to 10⁻⁹ M substance P was inhibited by the test compound) for the tested compounds.

Table 6

Co. No.	IC ₅₀ (in 10 ⁻⁹ M)	Co. No.	IC ₅₀ (in 10 ⁻⁹ M)	Co. No.	IC ₅₀ (in 10 ⁻⁹ M)
5	4.61	51	1.35	97	1.58
17	1.68	52	1.10	99	1.46
19	0.54	53	0.35	101	0.75
22	0.37	55	2.8	102	1.85
24	0.64	56	3.25	104	0.30
25	0.79	58	0.24	105	1.05
26	2.75	59	1.20	107	0.96
27	0.13	61	15.2	115	2.23
28	13.3	62	0.24	119	2.81
29	0.45	63	8.38	120	0.82
33	0.60	65	6.39	121	2.77
34	0.35	68	5.88	122	1.68
35	17.0	69	1.57	124	0.06
36	2.31	70	0.29	128	0.35
37	9.60	73	5.73	132	2.08
38	0.86	76	14.1	133	0.62
42	0.93	85	0.15	134	0.04
43	5.63	86	2.13	135	0.01
44	8.34	87	1.90	136	0.31
45	0.15	91	0.07	137	0.23
46	0.42	92	0.78	138	0.16
48	0.26	93	4.99	139	0.13
49	0.59	94	0.42		
50	2.43	95	0.10		

Example C.2 : Antagonism of substance P induced plasma extravasation in guinea-pigs

- 5 Plasma extravasation was induced by injection of substance P (2 mg/kg) in the femoral artery of female guinea-pigs. Evans Blue dye (30 mg/kg) was injected simultaneously. The test compound or solvent was administered 1 hour prior to substance P injection. 10 minutes after challenge, the animals were checked for blue colouring (a direct measure for plasma extravasation) of the nose, the forepaws, and the conjunctiva. 30 minutes
- 10 after challenge, the animals were sacrificed by CO₂ gas inhalation and checked for blue colouring of the trachea and the urinary bladder. Doses which actively inhibit substance

P-induced plasma extravasation are defined as those doses at which only 1/3 or less of the total surface area of the nose, forepaws, conjunctiva, trachea or urinary bladder are coloured blue by an intensive extravasation. Table 7 lists the lowest active doses (LAD) in mg/kg for the tested compounds.

5

Table 7

Co. No.	LAD (in mg/kg)				
	nose	forepaws	conjunctiva	trachea	urinary bladder
8	10.0	10.0	10.0	> 40.0	> 40.0
12	> 40.0	> 40.0	> 40.0	> 40.0	40.0
16	40.0	40.0	40.0	> 40.0	> 40.0
17	10.0	10.0	10.0	> 40.0	10.0
19	2.50	2.50	2.50	10.0	> 40.0
21	10.0	10.0	10.0	> 40.0	10.0
22	2.50	2.50	2.50	10.0	> 40.0
23	10.0	10.0	> 40.0	> 40.0	> 40.0
24	2.50	2.50	10.0	10.0	> 40.0
25	2.50	2.50	10.0	> 40.0	> 40.0
26	10.0	10.0	20.0	40.0	20.0
27	0.63	0.63	0.63	0.63	0.63
33	2.50	10.0	2.50	> 40.0	> 40.0
34	2.50	10.0	2.50	10.0	10.0
38	10.0	10.0	10.0	> 40.0	> 40.0
40	10.0	10.0	10.0	> 40.0	> 40.0
42	1.25	1.25	2.50	5.00	5.00
45	0.63	0.63	0.63	> 40.0	2.50
46	0.63	0.63	0.63	> 40.0	0.63
47	40.0	40.0	40.0	> 40.0	> 40.0
48	2.50	2.50	2.50	2.50	2.50
49	2.50	2.50	2.50	10.0	> 40.0
50	10.0	10.0	10.0	10.0	> 40.0
52	0.63	0.63	2.50	10.0	10.0
53	1.25	1.25	1.25	2.50	2.50
56	10.0	10.0	10.0	40.0	2.50
59	2.50	2.50	2.50	5.00	5.00
68	10.0	10.0	> 40.0	> 40.0	> 40.0
70	10.0	10.0	10.0	10.0	10.0

Co. No.	LAD (in mg/kg)				
	nose	forepaws	conjunctiva	trachea	urinary bladder
73	10.0	10.0	10.0	> 40.0	> 40.0
74	10.0	10.0	10.0	> 40.0	> 40.0
82	2.50	2.50	2.50	10.0	> 40.0
83	0.63	0.63	2.50	> 40.0	0.63
85	2.50	2.50	2.50	2.50	10.0
87	10.0	10.0	10.0	10.0	> 40.0
90	10.0	10.0	10.0	10.0	> 40.0
94	2.50	2.50	2.50	10.0	10.0
95	0.31	0.31	0.31	0.63	2.50
96	10.0	10.0	10.0	> 40.0	> 40.0
101	10.0	10.0	10.0	> 40.0	> 40.0
103	2.50	2.50	2.50	10.0	2.50
105	2.50	2.50	2.50	> 40.0	> 40.0
107	2.50	2.50	2.50	2.50	10.0
119	2.50	2.50	2.50	10.0	> 40.0
128	0.63	0.63	0.63	> 40.0	10.0
132	10.0	10.0	10.0	10.0	10.0
133	2.50	2.50	2.50	10.0	10.0
134	10.0	10.0	10.0	10.0	10.0
135	0.63	0.63	0.63	2.50	> 40.0
136	2.50	2.50	2.50	2.50	2.50
137	2.50	2.50	2.50	2.50	2.50
138	2.50	2.50	2.50	10.0	> 40.0
139	2.50	2.50	2.50	2.50	2.50

D. Composition examples

"Active ingredient" (A.I.) as used throughout these examples relates to a compound of formula (I) a pharmaceutically acceptable addition salt, a stereochemically isomeric form thereof or a *N*-oxide form thereof.

Example D.1 : ORAL DROPS

500 Grams of the A.I. was dissolved in 0.5 l of 2-hydroxypropanoic acid and 1.5 l of the polyethylene glycol at 60~80°C. After cooling to 30~40°C there were added 35 l of polyethylene glycol and the mixture was stirred well. Then there was added a solution of 1750 grams of sodium saccharin in 2.5 l of purified water and while stirring there were added 2.5 l of cocoa flavor and polyethylene glycol q.s. to a volume of 50 l, providing an oral drop solution comprising 10 mg/ml of A.I. The resulting solution was filled into suitable containers.

Example D.2 : ORAL SOLUTION

9 Grams of methyl 4-hydroxybenzoate and 1 gram of propyl 4-hydroxybenzoate were dissolved in 4 l of boiling purified water. In 3 l of this solution were dissolved first 10 grams of 2,3-dihydroxybutanedioic acid and thereafter 20 grams of the A.I. The latter solution was combined with the remaining part of the former solution and 12 l 1,2,3-propanetriol and 3 l of sorbitol 70% solution were added thereto. 40 Grams of sodium saccharin were dissolved in 0.5 l of water and 2 ml of raspberry and 2 ml of gooseberry essence were added. The latter solution was combined with the former, water was added q.s. to a volume of 20 l providing an oral solution comprising 5 mg of the active ingredient per teaspoonful (5 ml). The resulting solution was filled in suitable containers.

Example D.3 : FILM-COATED TABLETSPreparation of tablet core

A mixture of 100 grams of the A.I., 570 grams lactose and 200 grams starch was mixed well and thereafter humidified with a solution of 5 grams sodium dodecyl sulfate and 10 grams polyvinylpyrrolidone in about 200 ml of water. The wet powder mixture was sieved, dried and sieved again. Then there was added 100 grams microcrystalline cellulose and 15 grams hydrogenated vegetable oil. The whole was mixed well and compressed into tablets, giving 10.000 tablets, each containing 10 mg of the active ingredient.

Coating


To a solution of 10 grams methyl cellulose in 75 ml of denaturated ethanol there was added a solution of 5 grams of ethyl cellulose in 150 ml of dichloromethane. Then there were added 75 ml of dichloromethane and 2.5 ml 1,2,3-propanetriol. 10 Grams of polyethylene glycol was molten and dissolved in 75 ml of dichloromethane. The latter solution was added to the former and then there were added 2.5 grams of magnesium octadecanoate, 5 grams of polyvinylpyrrolidone and 30 ml of concentrated colour suspension and the whole was homogenated. The tablet cores were coated with the thus obtained mixture in a coating apparatus.

Example D.4 : INJECTABLE SOLUTION

1.8 Grams methyl 4-hydroxybenzoate and 0.2 grams propyl 4-hydroxybenzoate were dissolved in about 0.5 l of boiling water for injection. After cooling to about 50°C there were added while stirring 4 grams lactic acid, 0.05 grams propylene glycol and 4 grams of the A.I.. The solution was cooled to room temperature and supplemented with water for injection q.s. ad 1 l, giving a solution comprising 4 mg/ml of A.I.. The solution was sterilized by filtration and filled in sterile containers.





Claims

1. A compound of formula




a *N*-oxide form, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein

- n* is 0, 1 or 2;
 10 *m* is 1 or 2, provided that if *m* is 2, then *n* is 1;
p is 1 or 2;
 =*Q* is =O or =NR³;
X is a covalent bond or a bivalent radical of formula -O-, -S-, -NR³-;
*R*¹ is Ar¹, Ar¹C₁₋₆alkyl or di(Ar¹)C₁₋₆alkyl, wherein each C₁₋₆alkyl group is
 15 optionally substituted with hydroxy, C₁₋₄alkyloxy, oxo or a ketalized oxo
 substituent of formula -O-CH₂-CH₂-O- or -O-CH₂-CH₂-CH₂-O-;
*R*² is Ar², Ar²C₁₋₆alkyl, Het¹ or Het¹C₁₋₆alkyl;
*R*³ is hydrogen or C₁₋₆alkyl;
L is hydrogen; Ar³; C₁₋₆alkyl; C₁₋₆alkyl substituted with 1 or 2 substituents
 20 selected from hydroxy, C₁₋₆alkyloxy, Ar³, Ar³C₁₋₆alkyloxy and Het²;
 C₃₋₆alkenyl; Ar³C₃₋₆alkenyl; di(Ar³)C₃₋₆alkenyl or a radical of formula



-60-



wherein each q independently is 2, 3 or 4;

each r is 0, 1, 2, 3 or 4;

5 each Y^1 independently is a covalent bond, -O- or NR^3 ;

Y^2 is a covalent bond, C_{1-4} alkanediyl or $-\text{C}_{1-4}\text{alkylNR}^3$;

each $-\text{A}=\text{B}-$ independently is a bivalent radical of formula $-\text{CH}=\text{CH}-$, $-\text{N}=\text{CH}-$ or $-\text{CH}=\text{N}-$;

each R^4 independently is hydrogen, C_{1-6} alkyl, Ar^2 or $\text{Ar}^2\text{C}_{1-6}$ alkyl;

10 R^5 is hydrogen, C_{1-6} alkyl or Ar^3 ;

R^6 is C_{1-6} alkyl, Ar^3 , $\text{Ar}^3\text{C}_{1-6}$ alkyl, $\text{di}(\text{Ar}^3)\text{C}_{1-6}$ alkyl, $\text{Ar}^3\text{C}_{3-7}$ cycloalkyl, or indolyl;

R^7 is Ar^3 ; $\text{Ar}^3\text{C}_{1-6}$ alkyl; $\text{di}(\text{Ar}^3)\text{C}_{1-6}$ alkyl; C_{1-6} alkyl; C_{3-7} cycloalkyl; C_{3-7} cycloalkyl substituted with Ar^3 ; oxazolyl; oxazolyl substituted with halo or C_{1-6} alkyl; thiazolyl; thiazolyl substituted with halo or C_{1-6} alkyl; imidazolyl; imidazolyl substituted with Ar^3 , C_{1-6} alkyl, $\text{Ar}^3\text{C}_{1-6}$ alkyl or halo; indolyl; indolyl substituted with C_{1-4} alkyl; 2,3,4-trihydroquinolyl; pyrrolidinyl or furanyl;

15 each R^8 independently is hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl or a radical of formula

$-\text{Alk}-\text{R}^{11}$ (b-1) or

$-\text{Alk}-\text{Z}-\text{R}^{12}$ (b-2);

wherein Alk is C_{1-6} alkanediyl;

Z is a bivalent radical of formula -O-, -S- or $-\text{NR}^3$;

25 R^{11} is phenyl; phenyl substituted with 1 or 2 substituents selected from halo, C_{1-6} alkyl or C_{1-6} alkyloxy; furanyl; furanyl substituted with 1 or 2 substituents selected from C_{1-6} alkyl or hydroxy C_{1-6} alkyl; thienyl; thienyl substituted with 1 or 2 substituents selected from halo or C_{1-6} alkyl; oxazolyl; oxazolyl substituted with 1 or 2 C_{1-6} alkyl substituents; thiazolyl; thiazolyl substituted with 1 or 2 C_{1-6} alkyl substituents; pyridinyl or pyridinyl substituted with 1 or 2 C_{1-6} alkyl substituents;

30 R^{12} is C_{1-6} alkyl or C_{1-6} alkyl substituted with hydroxy, carboxyl or C_{1-6} alkyloxycarbonyl;

- Ar¹ is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, C₁₋₄alkyl, haloC₁₋₄alkyl, cyano, aminocarbonyl, C₁₋₄alkyloxy or haloC₁₋₄alkyloxy;
- Ar² is naphthalenyl; phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from hydroxy, halo, cyano, nitro, amino, mono- or di(C₁₋₄alkyl)amino, C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkyloxy, haloC₁₋₄alkyloxy, carboxyl, C₁₋₄alkyloxycarbonyl, aminocarbonyl and mono- or di(C₁₋₄alkyl)aminocarbonyl;
- Ar³ is phenyl or phenyl substituted with 1, 2 or 3 substituents selected from halo, hydroxy, amino, nitro, aminocarbonyl, C₁₋₆alkyl, haloC₁₋₆alkyl or C₁₋₆alkyloxy;
- Het¹ is a monocyclic heterocycle selected from pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl and benzothieryl; each monocyclic and bicyclic heterocycle may optionally be substituted on a carbon atom by 1 or 2 substituents selected from halo, C₁₋₄alkyl or mono-, di- or tri(halo)methyl; and
- Het² is a heterocycle selected from 1,4-dihydro-5-oxo-tetrazol-1-yl, imidazo[1,2-a]pyridinyl, oxazolyl or imidazolyl; each of said heterocycles may be substituted with 1 or where possible 2 substituents selected from C₁₋₄alkyl and Ar³.
2. A compound according to claim 1 wherein L is hydrogen; C₁₋₆alkyl; C₁₋₆alkyl substituted with hydroxy; C₃₋₆alkenyl; Ar³; Ar³C₁₋₆alkyl; di(Ar³)C₁₋₆alkyl; Ar³C₃₋₆alkenyl; di(Ar³)C₁₋₆alkenyl; or a radical of formula (a-1), (a-2), (a-4) or (a-5) wherein
- R⁷ is Ar³; Ar³C₁₋₆alkyl; di(Ar³)C₁₋₆alkyl; C₁₋₆alkyl; C₃₋₇cycloalkyl; C₃₋₇cycloalkyl substituted with Ar³; oxazolyl; oxazolyl substituted with halo or C₁₋₆alkyl; thiazolyl; thiazolyl substituted with halo or C₁₋₆alkyl; imidazolyl; imidazolyl substituted with Ar³, C₁₋₆alkyl, Ar³C₁₋₆alkyl or halo; pyrrolidinyl or furanyl;
- Ar³ is phenyl or phenyl substituted with 1, 2 or 3 substituents selected from halo, hydroxy, amino, aminocarbonyl, C₁₋₆alkyl, haloC₁₋₆alkyl or C₁₋₆alkyloxy;
- Het¹ is a monocyclic heterocycle selected from pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from

quinoliny, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl and benzothieryl; each monocyclic and bicyclic heterocycle may optionally be substituted on a carbon atom by 1 or 2 substituents selected from halo, C₁₋₄alkyl or mono-, di- or tri(halo)methyl.

- 5 3. A compound as claimed in claim 1 or 2 wherein R¹ is Ar¹C₁₋₆alkyl, R² is phenyl substituted with 2 substituents selected from methyl and trifluoromethyl, X is a covalent bond and =Q is =O.
- 10 4. A compound as claimed in any one of claims 1 to 3 wherein n and m are 1 and p is 1 or 2.
- 15 5. A compound as claimed in any one of claims 1 to 4 wherein R¹ is phenylmethyl; R² is phenyl substituted with 2 substituents selected from methyl or trifluoromethyl; n, m and p are 1; X is a covalent bond; and =Q is =O.
- 20 6. A compound as claimed in any one of claims 1 to 4 wherein L is a radical of formula (a-2) wherein R⁴ is hydrogen or phenyl; r is 0 or 1; Y¹ is a covalent bond, -O- or -NH-; R⁷ is pyrrolidinyl; furanyl; 1-phenylcyclohexanyl; diphenylmethyl; or phenyl substituted with 1, 2 or 3 substituents each independently selected from methyl, methoxy or chloro.
- 25 7. A compound as claimed in claim 5 or 6 wherein the compound has the *trans* configuration.
8. A compound as claimed in claim 5 or 6 wherein the compound has the *cis* configuration.
- 30 9. A compound as claimed in claim 1, wherein L is hydrogen.
- 35 10. A compound as claimed in claim 1, wherein the compound is
 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-piperazine acetamide;
 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(1-phenylcyclohexyl)-1-piperazine acetamide;
 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-[4-[α-(1-pyrrolidinylcarbonyl)benzyl]-1-piperazinyl]piperidine;
 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-[1-[(2-methyl-5-oxazolyl)methyl]-1H-benzimidazol-2-yl]-1-piperazinyl]-2-(phenylmethyl)piperidine;

4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(4-trifluoromethylphenyl)methyl]-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide;
 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide.

5

11. A compound as claimed in claim 10, wherein the compound is

(+)-(B)-*trans*-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide;

(-)-(B)-*cis*-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide; or

10

(+)-(B)-*trans*-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide, (L)-malic acid (1:1).

12. A composition comprising a pharmaceutically acceptable carrier, and as active

15

ingredient a therapeutically effective amount of a compound as claimed in any one of claims 1 to 11.


13. A process of preparing a composition as claimed in claim 12, characterized in that a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as claimed in any one claims 1 to 11.

20

14. A compound as claimed in any one of claims 1 to 11 for use as a medicine.

15. A process of preparing a compound as claimed in claim 1, characterized by


25 a) reductively *N*-alkylating an intermediate of formula (II) wherein L and p are defined as in claim 1, with an intermediate of formula (II)



30 wherein R¹, R², X, Q, n and m are defined as in claim 1, in a reaction-inert solvent, in the presence of an appropriate reducing agent and optionally in the presence of a suitable complex-forming agent;


35 b) reacting an intermediate of formula (IV) wherein R², X and Q are defined as in claim 1 and W¹ is an appropriate leaving group with an intermediate of formula (V)

-64-




wherein R^1 , L , n , m and p are defined as in claim 1, in a reaction-inert solvent and in the presence of a suitable base;

- 5 c) reductively *N*-alkylating a piperazine derivative of formula (VII) wherein p is defined as in claim 1 and P^1 is a protective group, with an intermediate of formula (II)




- 10 wherein R^1 , R^2 , X , Q , n and m are defined as in claim 1, in a reaction-inert solvent, in the presence of an appropriate reducing agent and optionally in the presence of a suitable complex-forming agent, thus forming a compound of formula (I-c);

- 15 d) reductively *N*-alkylating a piperazine derivative of formula (VII) wherein p is defined as in claim 1 and P^1 is a protective group, with an intermediate of formula (VIII),




- 20 wherein R^1 , n and m are defined as in claim 1, in a reaction-inert solvent and in the presence of a suitable base, thus forming an intermediate of formula (XI); which may subsequently be reacted with an intermediate of formula (IV)




wherein W^1 is an appropriate leaving group, and X , Q and R^2 are defined as in claim 1, to form a compound of formula (I-c);

- e) deprotecting a compound of formula (I-c) using art-known deprotection techniques, thus forming a compound of formula (I-b);



- f) reacting a compound of formula (I-b) with an intermediate of formula (VI)



wherein L' is the same as L as defined in claim 1 but other than hydrogen and W^2 is an appropriate leaving group in a reaction-inert solvent and in the presence of a suitable base; thus forming a compound of formula (I-a);

and, if desired, converting compounds of formula (I) into each other following art-known transformations, and further, if desired, converting the compounds of formula (I), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or into a therapeutically active non-toxic base addition salt by treatment with a base, or conversely, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; and, if desired, preparing stereochemically isomeric forms or *N*-oxide forms thereof.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 96/04660

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D401/04 C07D405/14 C07D401/14 C07D413/14 C07D471/14
C07D417/14 C07D409/14 C07D471/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 11895 A (CIBA-GEIGY A.G.) 4 May 1995 see abstract ---	1,14
A	EP 0 532 456 A (CIBA-GEIGY A.G.) 17 March 1993 cited in the application see abstract ---	1,14
A	EP 0 655 442 A (FUJISAWA PHARMACEUTICAL CO., LTD.) 31 May 1995 cited in the application see examples ---	1,14
A	EP 0 625 509 A (ZENECA LIMITED) 23 November 1994 see abstract ---	1,14

	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *G* document member of the same patent family

Date of the actual completion of the international search

21 January 1997

Date of mailing of the international search report

31.01.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Frelon, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 96/04660

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

ERROR: ioerror
OFFENDING COMMAND: image

STACK:

-savelevel-

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.